

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083439 A1

(51) International Patent Classification⁷: **C12N 15/62**,
15/63, 15/70, 11/00

(21) International Application Number:
PCT/TR2003/000019

(22) International Filing Date: 20 March 2003 (20.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **SABANCI UNIVERSITESI [TR/TR]**; Orhanli, 34956 Tuzla-Istanbul (TR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SAHIN, Erinc** [TR/TR]; Sabanci Universitesi, Faculty of Engineering & Natural Sciences, Biological Sciences & Bioengineering Program, Orhanli 34956 Tuzla- Istanbul (TR). **TARALP, Alpay** [TR/TR]; Sabanci Universitesi, Faculty of Engineering & Natural Sciences, Biological Sciences &

Bioengineering Program, Orhanli 34956 Tuzla- Istanbul (TR). **SAYERS, Zehra** [TR/TR]; Sabanci Universitesi, Faculty of Engineering & Natural Sciences, Biological Sciences & Bioengineering Program, Orhanli 34956 Tuzla- Istanbul (TR).


(74) Agent: **ARKAN, Selda**; Alfa Patent Ltd. Co., Agaciragi Sokak 7-9, Pamir Apt. No:3, Gumussuyu, 34437 Istanbul (TR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: CIRCULAR RECOMBINANT PLASMID DNA CONSTRUCTS AND THEIR PROTEIN PRODUCTS, METHODS OF PREPARATION AND IMMOBILISATION OF PROTEINS ON SUPPORT



(57) Abstract: The invention relates to new circular recombinant plasmid DNA constructs and their protein products, to the use of said protein products in immobilisation, visualisation and quantification of enzymes and proteins on compatible support material. The invention also relates to a method of preparation and immobilisation of the protein on a compatible support material, to the immobilised proteins obtained by said method as well as the use of said immobilised proteins in several applications.

WO 2004/083439 A1

BEST AVAILABLE COPY



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *with amended claims*

7/PR/TS.

10/550226

CIRCULAR RECOMBINANT PLASMID DNA CONSTRUCTS AND THEIR PROTEIN PRODUCTS,
METHODS OF PREPARATION AND IMMOBILISATION OF PROTEINS ON SUPPORT

The invention relates to new circular recombinant plasmid DNA constructs and their protein products, to the use of said protein products in immobilization, visualisation and quantification of enzymes and proteins on compatible support material. The invention also relates to a method of preparation and immobilisation of the protein on a compatible support material, to the immobilised proteins obtained by said method as well as the use of said immobilised proteins in several applications.

The invention concerns the general fields of recombinant plasmid DNA construction, recombinant protein expression, protein detection and quantification, protein immobilisation, arraying, orientation and applications of immobilised proteins. The general application of immobilised proteins and enzymes has played a central role in the expansion of biotechnology and synthesis-related industries.

For immobilising the proteins the following technologies are currently being used:

- Adsorption technology has the advantage that the protein-surface interaction is non-covalent and thus precludes any potentially disruptive chemical modifications associated with covalent immobilization, affording enzymes that often retain good, albeit perhaps altered biological activity, but with the common disadvantage of leaching of adsorbed enzymes from the surface and being lost in time. Although adsorption has the said disadvantage, other major advantages include rapid and facile preparation of the material.
- Encapsulation technology, like the above said adsorption technology, features many advantages associated with non-covalent protein-surface interactions, particularly the very native-like properties of matrix-enclosed enzymes. In addition, enzymes are easily encapsulated and well retained by the support. A related disadvantage however may be poor substrate accessibility, leading to slowed kinetics or lost apparent activity in the case of large substrates.
- Cross-linking technology features the advantages and disadvantages normally associated with covalent modification, one advantage being that protein is well retained on the support. A typical disadvantage of covalent modification is the possibility of loss of biological function as a result of chemical reaction or conditions imposed during the immobilization protocol. A potential advantage/disadvantage defined by context is the alteration of biological function. In the case of cross-linking technology, another disadvantage is the waste of useful biocatalyst since clumps of enzymes are often bound together, intertwined with the support. Under such conditions, diffusional

limitations may define the effective enzyme concentration to only those residing near the surface. Furthermore, the dynamic mobility of one enzyme may be impeded by virtue of being anchored to a neighbouring enzyme.

5 ➤ Covalent bonding, like above mentioned cross-linking technology, features the advantage of binding enzyme irreversibly to a surface. The observation of poor or altered activity has introduced modifications to the original method, in which a linker strand separating enzyme and surface imposes a distance constraint, thus restoring much native-like activity with possible exception to site-specific alterations normally associated with covalent modification of protein groups. More often than non-covalent methods, the conditions required to achieve covalent bonding may require harsh 10 conditions that lead to enzyme instability and deactivation.

Applicants refer to Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol. 135 (K. Mosbach, Ed) Academic Press, 1987, NY, Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol.137 (K. Mosbach, Ed) Academic Press, 1988, NY; 15 Immobilisation of enzymes and cells (G.F. Bickerstaff, Ed.) Humana Press, 1997, NJ, USA, Immobilised biomolecules in analysis: A practical approach (T. Cass and F.S. Ligler, Eds) Oxford University Press, 1998, NY. G.P. Royer (1974) *Supports for immobilized enzymes* CHEMTECH 4, 699.

Until now tags have been largely limited to poly-His for the reason that it binds to a surface 20 through a coordinating Ni ion. An exception is the work of Nock et al. (S. Nock, J.A. Spudich and P. Wagner (1997) "Reversible, site-specific immobilisation of polyarginine-tagged fusion proteins on mica surfaces" FEBS Letters 141, 233-238) Nonspecific polymer-surface interactions have been discussed very nicely in B. Jonsson, B. Lindman, K. Holmberg and B. Kronberg, Interaction of Polymers with Surfaces: in surfactant and 25 polymers in aqueous solution, John Wiley and Sons, 1998, NY.

Alignment of proteins on a surface using related methods are also given in Y. Harada, K. Yasuda, S. Nomra, N. Kajimura and Y. C. Sasaki (1998) Vectorially Oriented Fixation of Membrane-Embedded Bacteriorhodopsin onto an Inert Base" Langmuir 14, 1829-1835.

The following technologies are currently applied in biotechnological fields:

30 35 Multiple histidine residues (His-tag) in series have been applied for the selective purification of recombinant proteins. This technology is already being used for chromatographic purification of genetically engineered proteins coupled with nickel bearing columns. Applicants refer to Inouye, S. et al. "Aequorea green fluorescent protein: Expression of the gene and fluorescence characteristics of the recombinant protein" FEBS Letters 341 (1994) pages 227-280.

With explosive developments of the proteomic and genomic era, recombinant proteins are sought in large amounts for research, diagnostic and industrial purposes. While large amounts of various proteins can be produced, much research or applied work has experienced setbacks on the basis of poor purity of proteinaceous starting material. To 5 purify proteins further, a great number of techniques and strategies are being used and developed by scientists. One purification strategy in particular uses the affinity of homo-oligomers or special amino acid sequences to appropriate materials such as metal ion bearing surfaces. In this strategy, the cell lysate is applied onto an affinity material for binding. The non-specific proteins of the organism (which do not have the homo-oligomer 10 tail) are washed away. The recombinant protein, which is of interest for production in higher amounts, is retained by this process and a purification is achieved. Applicants refer to Dyke, Michael W. Van; Siritto, Maro and Sawadogo, Michèle "Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain", Gene, Col.111, Issue 1, 1 Feb. 1992, pages 99-104.

15 Fluorescent proteins are readily being used for identifying the location of proteins *in situ* by using fusion protein strategies. Applicants refer to Green fluorescent protein: properties, applications and protocols (M. Chalfie, S. Kain, Eds.) Wiley-Liss, 1998, NY; Protein localisation by fluorescence microscopy: a practical approach (VJ Allan, Ed.) Oxford University Press, 2000, NY; Imprint oxford; New York: Oxford University Press, c2000;

20 Oancea, E. et al "Green Fluorescent Protein (GFP)-tagged Cysteine-rich Domains from protein Kinase Cas Fluorescent Indications for Diacylglycerol Signalling in Living Cells "The Journal of Cell Biology, Volume 140, No.3, February 9, 1998, pages 485-498.

Multiple cloning site is a special sequence available in all commercially available plasmids, having the property of being cut by sequence specific enzymes. MCSs are normally used 25 to insert genes in order to clone or express foreign genes in a host organism. Applicants refer to J. Sambrook and D. W. Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.

As the efficiency, selectivity and maximum attainable loading of enzymes upon 30 commercially produced surfaces bear strongly on product performance, much effort has been invested to introduce user-friendly, selective, vectorially orienting and easy-to-quantify methods of immobilisation. However there is up to now no process enabling the direct immobilisation of proteins with facility, ease of detection and quantification.

An aim of the present invention is to provide a two-component system, described by a protein encoded by a recombinant plasmid DNA construct and an activated support

material, which permits the direct immobilisation and purification of enzymes and proteins with unsurpassed facility and ease of detection.

It is also an aim of the present invention to provide a two-component system, which permits easy visual detection and quantification through light emission.

5 It is another aim of the present invention to provide a protein encoded by a recombinant plasmid DNA construct permitting to incorporate additional restriction enzyme sites within the multiple cloning site.

It is another aim of the present invention to provide an immobilisation method, which does not require metal ion unlike established purification methods based on His-tag interactions,

10 the interaction between surface and histidine being a direct interaction.

It is another aim of the present invention to provide a technique that can be extended to any protein tag linked to any expressed protein as long as the surface is designed to bear affinity for it.

15 It is another aim of the present invention to provide a novel recombinant plasmid construct, specialised for expression and directional immobilisation of any fusion protein or enzyme, permitting easy visualisation and better quantification upon surfaces.

It is another aim of the present invention to afford orientation and arraying of enzymes along a surface.

20 Finally it is an aim of the present invention to provide a large distance separating protein and surface to enable immobilised enzymes to display native-like characteristics, which may prove advantageous in certain cases.

The above aims have been achieved by Applicants invention.

25 The invention relates to a circular recombinant plasmid DNA construct encoding a) a protein tag, b) a visual marker protein, and containing c) a multiple cloning site suitable for insertion of an additional gene, characterised in that the gene sequence encoding the protein tag and the visual marker protein are specifically designed and engineered at the DNA level for respectively a) immobilisation purposes and b) visualisation and quantification purposes at the protein level.

30 The protein tag may be chosen from the group containing lysine (lys), histidine (his), tyrosine (tyr), phenylalanine (phe), arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate, asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val), tryptophan (trp). The protein tag may be a histidine-tag such as a polyhistidine variant, in particular (6X) histidine.

The visual marker protein may be chosen from the group containing fluorescent or phosphorescent proteins. The fluorescent protein may be chosen from the group containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as their variants and/or mutants.

5 The multiple cloning site contains restriction enzyme recognition sites. The restriction enzyme recognition site is chosen from the group containing Sac I, Sal I, Hid III, Eag I, Not I. The construct further contains a frame adapter of variable length between the visual marker and protein tag genes.

The invention also relates to a protein expressed by circular recombinant plasmid DNA
10 construct cited above, wherein in the MCS adjacent to the visual marker, it further contains an additional target protein and in that the tag is suitable to interact directly with appropriate surface pendant groups of a support material. The protein may be a fusion protein.

The invention further relates to the use of the protein, in immobilisation and visualisation of proteins on compatible support material.

15 One other aspect of the invention is a method for preparing and immobilising a protein on a support material, said method contains the steps of:

- a) Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a multiple cloning site suitable for insertion of a target protein to be immobilised,
- b) inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
- c) initiating protein expression.
- d) Optionally pre-treating the support material;
- e) Incubating the protein and support material together, wherein the protein is immobilised to the support via specific tag-surface interactions;
- f) Washing away the non-specific biomolecules;
- g) Optionally quantifying the fluorescence of the visual marker protein;
- h) Optionally releasing the target protein.

30 The support material is chosen from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.
The support material is preferably chosen from the group containing polymers, silicon dioxides, aluminium oxides, titanium oxides, magnesium oxides, borates, metals and other
35 metal oxides.

The polymers may be chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters polysulfones, polyethersulfones, polyethersulfides, polyimines, polyethyleneglycols, 5 polypropyleneglycols, polyimides, polycarbonates, polyurethanes,

The polymer surface may be chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide 10 groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals. The support material may be carboxylated polystyrene.

15 The invention also relates to the immobilised protein construct obtained by the above method, wherein it is covalently or non-covalently bonded to the support material. The immobilised protein construct is non-covalent and yet freely accessible and retained like proteins immobilised in the covalent sense.

20 Finally the invention relates to the use of the immobilised protein constructs in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.

FIGURES

Figure 1 is the Schematics of Experimental: Preparation of a recombinant plasmid
25 DNA construct for immobilisation

Figure 2 shows the Resultant plasmid

Figure 3 is a scheme of immobilisation

Figure 4 shows the Successful Immobilisation of the GFPimm protein

Figure 5 is the graphical representation of well fluorescence

30 Figure 6 is the infrared spectroscopic profile of the topmost micron layer of native polystyrene;

Figure 7 is the infrared spectroscopic profile of the topmost micron layer of oxidized polystyrene, implying the formation of surface hydroxyl and carboxylic acid and possibly ketone functionalities.

DEFINITIONS

Protocol 1 is from QIAGEN® Plasmid Purification Handbook 12/2002 pages 16-20 "Plasmid or Cosmid DNA Purification using QUIAGEN® Plasmid Midi and Maxi Kits".

5 Protocol 2 is from QIAquick Spin Handbook 07/2002, pages 23-24 "QIAquick Gel Extraction Kit Protocol using a microcentrifuge"

Protocol 3 is from QIAprep Miniprep Handbook 03/2002, pages 22-25 "QIAprep Spin Miniprep Kit Protocol using a microcentrifuge".

10 Protocol 4 is from Version I 020402 25-0006 of Probond Purification System "A manual of methods for purification of polyhistidine-containing recombinant proteins"

Sequence listing 1 is the GFP Gene

Sequence listing 2 is the pETM-11

Sequence listing 3 is the pETM-ADP.

15 Sequence listing 4 is the pGFPuv

Sequence listing 5 is the pETM-GFP-imm

The term frame adapter refers to the following sequence listing:

1 GTACGCCATG GGAGGCACGG TACCTTGTG

20 The term "native-like activity" refers to the activity of an immobilized enzyme which is not diminished significantly when compared to its activity in solution. "Native" in this case refers to solution phase for the enzyme.

25 The term "recombinant plasmid DNA construct" refers to an artificially constructed circular DNA, combining genes obtained from different organisms in nature, using molecular biology protocols.

25 The term "protein encoded by a recombinant plasmid DNA construct" refers to a recombinant protein which is the final product of protein synthesis where the recombinant plasmid DNA construct was used as the template and source of genetic information for the said synthesis.

30 The term "MAD peptide coding sequence" refers to a gene on the original pETM-11 plasmid, which was excised to modify the plasmid to provide space for insertion of GFP gene as a part of protocols resulting in the invention.

The term "restriction enzyme recognition site" refers to special sequences at which restriction enzymes cut DNA with a high specificity. Each restriction enzyme specifically cuts at its own recognition site on the DNA being engineered.

The term "expression vector or plasmid" refers to a plasmid specialized for high efficiency protein synthesis of a gene inserted in the expression vector's multiple cloning site.

The term "multiple cloning site or MCS" refers to a special sequence designed and artificially constructed on the plasmid, which has a number of restriction enzyme

5 recognition sites together, used to provide open ends for insertion of linear gene fragments in the circular plasmid. Production of open ends is performed by digestion of circular plasmid with restriction enzymes that only cut at their specific recognition sites while combining ends of linear gene and open ends of plasmid is performed by ligation with DNA ligase enzyme.

10 The term "protein expression" refers to synthesis of proteins using genetic information in the gene for the protein.

The term "DNA level" refers to the type of activity, which is designed and/or performed on the gene before protein synthesis has taken place, but is affecting the protein.

15 The term "Visual marker protein" refers to a protein (such as GFP), which can be visualised by its fluorescence after it is excited by a characteristic wavelength of light.

20 The term "immobilisation" refers herein to protein attached to surfaces via a non-covalent interaction. The classic definition of immobilisation refers to covalent and non-covalent methods whereas the classically used terms referring exclusively to non-covalent binding are adsorption or entrapment. The work herein attempts to contrast the facility and generality of immobilisation using the non-covalent tags against the normal methods based upon covalent linkers.

25 The term "support" refers to any polymeric solid in membrane, particle or wall format, natural or synthetic, porous or nonporous, of organic, inorganic, metallic, or combined composition thereof in the microscopic, mesoscopic or macroscopic length scale, that may or may not be soluble, even transiently under certain conditions, and which bears appropriate surface physico-chemical traits to interact favourably with the fusion protein tag, affording immobilisation. Typical examples of synthetic polymers, out of which composites may also be fashioned, as well as example composites, include, but are not limited to, polyolefins such as polystyrene and related side-chain derivatives such as 30 carboxylated polystyrene, Dowex or chloromethylpolystyrene, polypropylene and side-chain derivatives such as carboxylated polypropylene, polyethylene and related side-chain derivatives, polymethylmethacrylate and related side-chain derivatives such as methyl esters, polyacrylate and side-chain derivatives such as polyacrylamide and polyacrylonitrile, polyethersulfones, polyphenylene, polyphenylenesulfide, polysulfone, 35 graphite and active carbon, polyisobutylene, polyisoprene, polycarbonates, polyphenols

such as resol and Novolac, polyesters such as polyalkanoate and polyethyleneteraphthalate, polyamides such as Nylon, polyimides, polyimines, polyvinylalcohols and derivatives, polyethyleneglycol, polyvinylesters, polyethers, polyvinylchloride, polytetrafluoroethylene, polyepoxides, polyurethanes, 5 polychlorotrifluoroethylene, cellulose and nitrocellulose, agarose and related polysaccharides, perfluorinated polymers such as Nafion, silicones, soft glass, borosilicate glass, quartz glass, and other derivatives of silicon dioxide, metal oxides such as iron oxide, titanium dioxide, and aluminum oxide, metal silicates and aluminates such as magnesium silicate and aluminum silicate. Typical examples of natural polymers include, 10 but are not limited to kaolin, diatomaceous earth, sand, volcanic pumice and other inorganics, coal, wood or cellulose, alginic acid, agar, chitin and derivatives, amylose, glycogen, DNA and other polysaccharides, paraffins and triglycerides.

The term "purified" as applied to proteins herein refers to a composition wherein the desired protein comprises at least 80% of the total protein component in the composition.

15 The composition may contain other compounds such as carbohydrates, salts, lipids, solvents and the like without affecting the determination of the percentage purity.

Detailed description of the invention

I. Preparation of a recombinant Plasmid DNA construct for immobilisation

For this preparation reference is made to Figure 1, wherein a) shows a native vector DNA, 20 that is a protein tag coding plasmid, b) shows a native vector DNA encoding the visual marker protein; c) shows the modified protein tag coding plasmid modified for inserting the visual marker protein in correct frame and d) shows the final recombinant vector specialised for immobilisation of any enzyme or protein.

Multiple adjacent histidine residues incorporated into a protein structure have been applied 25 for the selective purification of recombinant proteins by means of a stepwise process in which the His-tag is recognised, the target protein is immobilised, the non-specific biomolecules are washed away, and the target protein is desorbed. A related process is used herein.

Multiple cloning site (MCS) is a special sequence that has the property of being cut by 30 sequence specific enzymes. MCS are normally used to insert genes in order to clone or express foreign genes in a host organism. In Applicants' system, the multiple cloning site may be used in order to introduce the gene for the enzyme to be immobilised. Another approach may be to introduce additional restriction enzyme sites to MCS in order to enhance space availability and insertion combinations for the gene of the enzyme to be 35 immobilised.

A commercially available, protein tag coding plasmid like the pETM-11 given in Seq. List. 2 is purified and digested to excise MAD protein coding sequence, which is the MAD gene (Fig 1a). The expression vector (plasmid) pETM-11 in particular was chosen for the reason that its histidine-rich tag could facilitate the subsequent purification and immobilisation of expressed proteins and direct their surface orientation. pETM-11 also bears a cleavable linker gene which is a DNA sequence coding for a small sequence of amino acids that has a specific chemical reactivity allows controlled cleavage by the addition of the appropriate external agent.

On the other hand a frame adapter having the following sequence listing is synthesised.

10 The frame adapter was designed to code for a special sequence of amino acids (Met-Gly-Gly-Thr) forming a high flexibility region in the immobilisation adapter protein.

1 GTACGCCATG GGAGGCACGG TACCTTGTG

Then the frame adaptor is inserted into the modified plasmid to give a novel pETM-Adp plasmid like the one given in Seq. List. 3 (Fig 1c). Bacteria are transformed for amplification of plasmid and the amplified pETM-Adp plasmid is isolated from bacteria and stored.

15 Then the stored pETM-Adp plasmid is digested to make it ready for another insertion. On the other hand a commercially available native vector DNA like pGFPuv (encoding the visual marker protein GFP) given in Seq. List. 4 is digested to make it ready for insertion (Fig 1b).

20 The green fluorescent protein has served to identify the location of other proteins *in situ* by exploiting fusion protein strategies. Although in Applicants' model GFP variant is used, any fluorescent or phosphorescent protein such as Red FP, Yellow FP, Blue FP and/or their variants and mutants can also be used.

The strategy adopted was to fuse the plasmid to a GFPuv (green fluorescent protein) gene followed by a multiple cloning site. In principle, this multiple cloning site can be used to introduce the gene of any protein, barring size constraints. It would follow that the location and loading of immobilised proteins can be conveniently assessed on the basis of fluorescence emitted by the accompanying adaptor protein.

25 Then the GFPuv gene is inserted into pETM-Adp to give the novel pETM-GFP-Imm plasmid construct like the one given in Seq. List.5. This is the final recombinant vector specialised for immobilisation of any enzyme or protein. Bacteria are transformed for amplification of plasmid and the amplified pETM-GFP-Imm plasmid is isolated and stored.

30 The novel pETM-GFP-Imm plasmid construct does not contain the gene of enzyme to be immobilised but it is designed for another insertion using multiple cloning site after the visual marker protein. (Figure 2)

Figure 2 shows the final recombinant vector specialised for immobilisation of any enzyme or protein in that it has a special place preserved for the insertion of new restriction enzyme sites and the insertion of gene of the enzyme or any protein to be immobilised.

The production facilities of this vector as well as the affinity purification techniques of 5 proteins are established and cost-effective. More importantly, the advantages stated herein are not in any way compromised by disadvantages which are exclusive to this particular process.

II. Immobilisation of protein product of recombinant plasmid DNA on a compatible polymer surface

10 For this immobilisation reference is made to Figure 3 wherein an enzyme or protein (E) containing a visual marker protein (VM) is bonded through its tag (T) to the surface of a compatible support material (S).

Bacterial culture of the novel plasmid –pETM-GFP-Imm– bearing expression strains are grown. On the other hand bacterial culture of visual marker protein coding plasmid – 15 pGFPuv– bearing expression strains are grown. Then both bacterial cultures were lysed and GFPuv and protein tag containing GFPimm proteins are purified. For both proteins the sodium concentration is lowered and imidazole is removed by dialysis in preparation of surface binding.

The surface of the compatible support material is prepared. In this particular case the 20 polystyrene surface is oxidised in preparation for immobilisation. Polymer surfaces have been tailored using chemical methods to bear various functional groups. The carboxyl group in particular has been applied in the reversible/irreversible surface immobilisation of positively charged species as well as hydrogen bonding species.

GFPimm protein is bound to the surface of a compatible support material. Said compatible 25 support material can be a polymer, a biopolymer, a glass or a metal. A prefabricated surface and complementary tag showing good interaction with the surface is used.

The green fluorescent protein has served to identify the location of other proteins *in situ* by 30 exploiting fusion protein strategies. Although in Applicants' model a GFP variant is used, any fluorescent or phosphorescent protein such as Red FP, Yellow FP, Blue FP and their variants and/or mutants can be used. These fluorescent proteins can be used even in a combined manner that the different enzymes of the same enzymatic pathway can be immobilised and easily quantified on different regions of the same polymeric support.

Applicants' invention permits to avoid all disadvantages of immobilisation technology while benefiting from the advantages of said technology. In Applicants' system, polyhistidine tag

is used for ionic interaction between their positive charges and negative charge loaded on polymeric surface, the difference being that the interaction between surface and tag is direct as opposed to mediated by a coordinating metal ion.

Unlike established purification methods based on His-tag interactions, Applicants' immobilisation method does not require metal ion, the interaction between surface and histidine being a direct interaction.

Furthermore, Applicants' technique can be extended to any protein tag as long as the surface is designed to bear affinity for it. Similar approach may be applied to other protein tags with appropriate tailored surfaces provided that the tag and the surface have affinity to each other.

Measurements are made to show the binding. The distance separating protein and surface being large in comparison to many immobilisation methods, immobilised enzymes in particular are anticipated to display native-like characteristics.

It is made reference to Figures 4 and 5 wherein Figure 4 shows a photo with an integration time of 190ms and Figure 5 shows its fluorescence in relative fluorescence units.

Before taking the photo of Fig.4, GFPimm and GFPuv of approximately same concentration were incubated during 2 hours and washed 3 times with the appropriate buffer in which binding reaction occurred being different in that rinsing buffer does not contain any form of GFP. After 3 washes with buffer, 25mM sodium phosphate, 250mM NaCl solution (the pH was appropriately adjusted with NaOH), the wells were dried by inverting the well over paper towels and tapping the backs repeatedly.

TABLE
96 Well Plate Assay using Gemini XS fluorometer-dry well readings.

	0MAPS	1MAPS	2MAPS	empty
NoGFP	12,02	19,511	17,073	13,635
GFPpH6	23,96	64,387	62,106	20,444
GFPHispH6	63,792	274,97	443,267	76,069
GFPpH7	15,509	67,949	85,149	22,401
GFPHispH7	233,672	690,85	888,078	145,186
GFPpH8	16,176	78,776	89,982	23,807
GFPHispH8	99,532	250,865	344,894	50,509
EMPTY	12,462	13,748	13,114	13,251

The data of the above table and the Figures verify that GFPimm was selectively immobilised on carboxylated polystyrene at pH 6, 7 and 8 whereas native GFPuv was not similarly retained following repeated washings. Moreover, the data indicates that a non-specific interaction, albeit small in comparison, is still present between GFPimm and native 5 polystyrene. For this reason, the possibility of introducing tyrosine or tryptophan tags is also noteworthy, as they can in principle also bind to the aromatic surface via aromatic-aromatic stacking.

Unlike established purification methods based on His-tag interactions, a difference with the 10 technology herein is that no metal ion is required to enable the immobilisation event. The interaction between surface and histidine is a direct interaction between surface-pendent carboxyl groups and imidazole moieties of the his-tag in the protein.

The reversal of binding is facile in simple species that bear few positive charges. In systems involving much larger, multi-charged molecules such as proteins, the biomolecule is often immobilised by its own inertia. In these situations, proteins may in fact be 15 irreversibly immobilised even though no formal covalent bond is created. This relationship is particularly relevant in the short term but it can revert to a reversible association in time.

Since the distance separating protein and surface is large in comparison to many immobilisation methods, immobilised enzymes in particular are anticipated to display native-like characteristics, which may prove advantageous in certain cases.

20 Examples of alternative interactions include hydrogen-bonding, hydrophobic interactions such as base stacking and other ionic bondings such as positively charged ammonium sulfates and negatively charged amino acids.

Indeed examples of such interactions have been established, however, the notable 25 difference with the proposed technology herein is that the tag is specifically designed and engineered on the protein at the DNA level.

Fusion proteins potentially represent very common products of this technology. Proteins fused to GFPimm will feature a facile means of visualisation in addition to a facile means of purification. In applicants system GFP is used in order to visualise final location and quantify the immobilised enzyme that is fused to the fluorescent protein genetically.

30 Applicants' novel recombinant plasmid technology specialised for fusion protein expression and immobilisation, permits easy visualisation and better quantification upon surfaces. Fusion proteins potentially represent very common products of this technology. Proteins fused to the marker will feature a facile means of visualisation in addition to a facile means of purification.

The immobilisation strategy also required that a substrate surface respond selectively to the his-tag. To this end, Applicants devised several surfaces bearing linkers that could interact covalently or electrostatically with the imidazole functional group.

Now it is made reference to figures 6 and 7 wherein figure 6 is the infrared spectroscopic profile of the topmost micron layer of native polystyrene and figure 7 is the infrared spectroscopic profile of the topmost micron layer of oxidized polystyrene, showing the formation of surface hydroxyl and carboxylic acid and possibly ketone functionalities introduced for interacting with protein tag in the designed protein construct.

In Figure 7, 1 stands for H-O stretch of alcohol; 2: stands for H-O stretch of carboxylic acid; 10 3: stands for C=O stretch of carboxylic acid and ketone; 4: stands for C-O stretch of alcohol and carboxylic acid.

In summary Applicants' invention includes following advantages: 1) the flexibility to incorporate enzymes or any proteins or additional restriction enzyme sites within the multiple cloning site, 2) the flexibility to incorporate any amino-acid tags, 3) the flexibility to put distance between the surface and the protein, improving the likelihood that native-like activity of anchored proteins is retained; 4) the possibility to achieve spatial orientation of proteins and permit their arraying along a surface, 5) to permit easy visual detection and quantification through light emission and 6) to avoid exposing protein to potentially harmful chemical modifications.

20 Current work is directed at optimising the conditions of immobilisation, quantifying the bound protein, and characterising its function.

The following example is given for illustration purposes and does not restrict or limit whatsoever the invention.

EXAMPLE

25 **The Protocols used in the Example:**

QIAGEN Plasmid Purification Handbook 12/2002 Plasmid or Cosmid DNA Purification using QIAGEN Plasmid Midi and Maxi kits, pages 16-20.

QIAquick Spin Handbook 07/2002, QIAquick Gel Extraction Kit Protocol using a microcentrifuge", pages 23-24

30 QIAprep Miniprep Handbook 03/2002 "QIAprep Spin Miniprep Kit Protocol using a microcentrifuge", pages 22-25.

Protocol for ProBond Purification System, A manual of methods for purification of polyhistidine-containing recombinant proteins, Catalog no. K850-01, K851-01, K852-01, K853-01, K854-01 from www.invitrogen.com tech_service@invitrogen.com

Plasmids, Enzymes, Chemicals and Experimental Kits**and Buffers Used in the Example :**

• Acetic Acid	Riedel-de Haén, Catalog#: 27225, CAS 64-19-7
• Acrylamide: Bis-acrylamide	Sigma, Catalog#: A3699, CAS 79-06-1 and 110-26-9
5 • Agarose	Sigma, Catalog#: A-6138, CAS9012-36-6
• Ammonium persulfate	Carlo-Erba, Italy, Catalog#: 420627,
• Ampicillin	Sigma, Catalog#: A9518
• Boric Acid	Riedel-de Haén, Catalog#: 11607
• BSA (Bovine Serum Albumin)	Promega,
10 (10X concentrated)	supplied with Kpn I, Nco I and Sac I
• Distilled water, sterile, MilliQ filtered	Millipore, MilliQ Academic, France
• EDTA	Riedel-de Haén, Catalog#: 27248
• Ethanol	Riedel-de Haén, Catalog#: 32221
• Ethidium Bromide	Merck, Catalog#: OCO28942
15 • Frame Adapter	Synthesized by Seqlab, Germany (design E. Şahin)
• Glycerol	Riedel-de Haén, Catalog#: 15523
• HCl	Merck, Catalog#: 100314
• Imidazole	Sigma, Catalog#: I-2399
• IPTG	Promega, Catalog#: V39517
20 • Isopropanol	Riedel-de Haén, Catalog#: 24137
◦ Kanamycin	Sigma, Catalog#: K4000
◦ Kpn I	Promega, Catalog#: R634A
• Liquid nitrogen	Karbogaz, Turkey
• Luria Agar	Sigma, Catalog#: L-3147
25 • Luria Broth	Sigma, Catalog#: L-3022
• Lysozyme	Merck, Catalog#: 1.05281
• Mass Ruler DNA Ladder	Fermentas, Catalog#: #SM0393 High Range
• Mass Ruler DNA Ladder	Fermentas, Catalog#: #SM0383 Low Range
• 2-Mercaptoethanol	Aldrich Chemical Company, M370-1
30 • Micro-Spin™ G-25 Columns	Amersham Biosciences, Catalog#: 27-5325-01
• Multi-Core™ Buffer (10X)	Promega, supplied with Kpn I, Nco I and Sac I
• NaCl	Riedel-de Haén, Catalog#: 13423
• NaH ₂ PO ₄	Merck, Catalog#: 106370
• NaOH	Merck, Catalog#: 106462

	• Native Purification Buffer (5x) for ProBond	Composed of Na ₃ PO ₄ and NaCl. Preparation is given in Protocol 4 section.
	• Nco I	Promega, Catalog#: R651F
	• Nickel Chloride	Merck, 806722
5	• pETM-11	European Molecular Biology Laboratories, Germany
	• pGFPuv	Clontech, Germany
	• Polystyrene 96-well plate	TPP, TP92696
	• Polystyrene culture plate	TPP, TP93100
	• ProBond™ resin	Invitrogen, Catalog#: 46-0019
10	• Qiagen Midi-prep Plasmid Purification Kit	Qiagen, Catalog#: 12145 (All buffers in protocols are included)
	• Qiagen Mini-prep plasmid isolation kit	Qiagen, Catalog#: 27106 (All buffers in protocols are included)
	• Qiagen QIAquick	Qiagen, Catalog#: 28706 (All buffers in protocols are included)
15	Gel Extraction Kit	Qiagen, supplied with Qiagen Plasmid Isol. Kits
	• RNAase	Promega, Catalog#: R606A
	• Sac I	Sigma, Catalog#: L-4390
	• Sodium Dodecyl Sulphate	Promega, supplied with T4 DNA Ligase
	• T4 DNA Ligase Buffer (10X)	Promega, Catalog#: M180B
20	• T4 DNA Ligase	Sigma, Catalog#: T-7029
	◦ TEMED	Fluka, Catalog#: 93349
	• Tris	Composed of Tris, acetic acid and EDTA. For preparation see J. Sambrook and D. W. Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.
25	• Tris-Acetate-EDTA Buffer	Composed of Tris, acetic acid and EDTA. For preparation see J. Sambrook and D. W. Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.
30	• Tris-Borate-EDTA Buffer	Composed of Tris, acetic acid and EDTA. For preparation see J. Sambrook and D. W. Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.
	• Tris-HCl	Composed of Tris and HCl. Tris is dissolved to a given molarity and pH is adjusted with HCl.
35	• Urea	Merck, Catalog#: 1.12007.2500

Instruments and equipment used in the Example:

	Autoclave:	Hirayama, Hiclave HV-110, JAPAN
	Balance:	Sartorius, BP221S, GERMANY
		Schimadzu, Libror EB-3200 HU, JAPAN
	Centrifuge:	Eppendorf, 5415D, GERMANY
5		Hitachi, Sorvall RC5C Plus, USA
	Deepfreeze:	-80°C, Kendro Lab. Prod. Heraeus Hfu486 Basic, Germany
		-20° C, Bosch, TURKEY
	Dialysis tubes	CelluSep T3, Membrane Filtration Products Inc., USA
	Distilled Water:	Millipore, Elix-S, FRANCE
10		Millipore, MilliQ Academic, FRANCE
	Electrophoresis:	Biogen Inc., USA
		Biorad Inc., USA
	Filter membranes	0.2 µm filter: Millipore, Catalog# GNWP04700, USA
		0.45 µm filter: Millipore, Catalog# HNWP04700, USA
15	Fluorometer:	SPECTRAmax GEMINI XS, Molecular Devices Corporation, USA
	FPLC	ÄKTA FPLC, Amersham Biosciences
	FPLC Column	MonoQ Ion Exchange Chromatography Column (10/10), Amersham Biosciences
	Gel Documentation:	UVITEC, UVIdoc Gel Documentation System, UK
20		Biorad, UV-Transilluminator 2000, USA
	Heater Block:	Bioblock Scientific, FRANCE
	Ice Machine:	Scotsman Inc., AF20, USA
	Incubator:	Memmert, Modell 300, GERMANY
		Memmert, Modell 600, GERMANY
25	FT Infrared Spectrometer:	Equinox 55 TGA-IR, Bruker Optics Inc.
	with Attenuated Total Refl. Accessory	
	Laminar Flow:	Kendro Lab. Prod., Heraeus, HeraSafe HS12, GERMANY
	Magnetic Stirrer:	VELP Scientifica, ARE Heating Magnetic Stirrer, ITALY
		VELP Scientifica, Microstirrer, ITALY
30	Microliter Pipette:	Gilson, Pipetman, FRANCE
		Mettler Toledo, Volumate, USA
	Microwave Oven:	Bosch, TURKEY
	pH meter:	WTW, pH540 GLP MultiCal®, GERMANY
	Polystyrene 96-well plate	TPP, SWITZERLAND
35	Power Supply:	Biorad, PowerPac 300, USA
		Wealtec, Elite 300, USA
	Refrigerator:	+4° C, Bosch, TURKEY

	Shaker:	Forma Scientific, Orbital Shaker 4520, USA
		GFL, Shaker 3011, USA
		New Brunswick Sci., Innova™ 4330, USA
	Sonicator	Vibracell 75043, Bioblock Scientific, FRANCE
5	Spectrophotometer:	Schimadzu, UV-1208, JAPAN
		Schimadzu, UV-3150, JAPAN
		Secoman, Anthelie Advanced, ITALY
	Speed Vacuum:	Savant, Speed Vac® Plus Sc100A, USA
		Savant, Refrigerated Vapor Trap RVT 400, USA
10	Thermocycler:	Eppendorf, Mastercycler Gradient, GERMANY
	Vacuum:	Heto, MasterJet Sue 300Q, DENMARK
	Vortex:	Velp Scientifica, ITALY

Step 1: Preparation of vector for ligation:

15 pETM11 vector originally has a protein (MAD) coding sequence which is removed to modify the vector for using with larger inserts. For this purpose, enzymatic digestion of purified pETM-11 vector was performed using *Kpn* I and *Nco* I restriction enzymes.

A: Purification of pETM-11:

XL1-Blue *E.coli* strain containing pETM-11 plasmid was grown in 50 mL Luria Broth with 50 µg/mL final concentration of Kanamycin at 37°C, at 300 rpm overnight.
20 Overnight grown cultures are used for isolation of pETM-11 plasmid by using Protocol 1. Quantification is done by spectrophotometric absorbance measurement at 260 nm by using the formula: [DNA] = [Abs] x 50 ng/µl. The measurement value is verified with gel electrophoresis results.

B: Digestion of pETM-11 with *Kpn* I and *Nco* I:

25 • 56 µl pETM-11 vector (~5.6 µg)
• 8 µl Multi-Core™ buffer system
• 8 µl BSA
• 4 µl *Kpn* I
• 4 µl *Nco* I
30 3 hours incubation was performed at 37°C, digestion was verified with agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.
MAD coding sequence is removed from pETM-11 by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis following double digestion with *Kpn* I and *Nco* I. Larger fragment (pETM-11 without MAD) was isolated by using Protocol 2. Quantity estimation was done by 35 agarose gel electrophoresis analysis.

Step 2: Preparation of frame adapter for ligation:

The adapter was digested at both sides by *Kpn I* and *Nco I* restriction enzymes in six different Eppendorf tubes in parallel, by using the following protocol:

- 2 µl Adapter (0.025 nmol/µl)

5 • 4 µl Multi-Core™ buffer system

- 6 µl BSA
- 2 µl *Kpn I*
- 2 µl *Nco I*
- 24 µl dH₂O (MilliQ filtered, sterile)

10 Overnight incubation was performed at 37°C, 6 tubes of digests were combined together and desalting by passing two times through Micro-Spin™ G-25 Columns. Digestion verification and quantity estimation is performed by polyacrylamide urea gel electrophoresis (3 mL 30%:0.8% - Acrylamide:Bis-acrylamide; 500 µl 10xTBE; 2.1 gr urea; 1.5 mL dH₂O; 45µl APS; 3 µl TEMED).

15 Frame adapter 1 GTACGCCATG GGAGGCACGG TACCTTGTG

Step 3: Ligation:

“pETM-11 without MAD” was ligated with “frame adapter” in order to prepare the vector for insertion of GFP within the right frame of protein synthesis. A wide range of different concentration ratios were applied in order to optimise ligation in this specific case where insert is ~0.1% of the vector. The following protocol was used:

<u>PETM-11 + Adapter</u> <u>(1:0.2 (v:v))</u>	<u>pETM-11 + Adapter</u> <u>(1:0.8 (v:v))</u>	<u>PETM-11 + Adapter</u> <u>(1:10 (v:v))</u>	<u>Self Ligation</u> <u>(control)</u>
1µl pETM-11	1µl pETM-11	1µl pETM-11	1µl pETM-11
0.2 µl Adapter	0.8 µl Adapter	10 µl Adapter	2 µl Ligation buffer
2 µl Ligation buffer	2 µl Ligation buffer	2 µl Ligation buffer	1 µl Ligase
1 µl Ligase	1 µl Ligase	1 µl Ligase	16 µl dH ₂ O
15.8 µl dH ₂ O	15.2 µl dH ₂ O	6 µl dH ₂ O	

Ligations were performed at 25°C overnight.

Step 4: Transformation:

- 50 µl competent *E. coli* XL1-Blue cloning strain was added on overnight ligation mixes.

25 • Competent cell added ligation mixes were incubated 20 min on ice.

- Tubes were incubated at 42°C heater block for 3 minutes.

- 900 µl LB (without Kanamycin) was added to each ligation mix.
- LB added transformation mixes are incubated for 1.5 hours at 37°C with 190 rpm shaking.
- 100 µl and 400 µl aliquots were spread on Luria Agar+Kanamycin plates and the plates were incubated at 37°C incubator overnight.

5

Step 5: Colony Check for Presence of Insert:

5 colonies were picked one by one and grown overnight in 5 mL LB+ Kanamycin cultures individually at 37°C with 300 rpm shaking. Next day, plasmid isolation was performed by application of Protocol 3 to each overnight culture. Each isolated plasmid was digested by 10 either *Kpn* I or *Nco* I under the following conditions:

- 5 µl mini-prep isolated plasmid
- 1 µl Multi-Core™ buffer system
- 1 µl BSA
- 0.5 µl *Kpn* I OR *Nco* I for each mini-prep isolated plasmid
- 2.5 µl dH₂O (MilliQ filtered, sterile)
- Incubation for 3 hours at 37°C.

15

Digestion efficiency and presence of vector plasmid were detected by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis analysis in which uncut and cut original (unmodified) pETM-11 were also used as standards. The vector was quantified by 20 spectroscopic analysis at UV-visible wavelength range.

Step 5a -80 Stock Preparation:

After the presence of correct plasmids was verified with agarose gel electrophoresis, glycerol stocks of plasmid bearing colonies were prepared by the following protocol:

- To 850 µl overnight grown bacterial culture, 150 µl sterile glycerol was added.
- Mixed by vortexing.
- Frozen in liquid nitrogen.
- Kept at -80°C.

25

Step 6- Preparation of adapter bearing vector (pETM-Adp) for ligation:

pETM-Adp was prepared for ligation with GFP gene by enzymatic digestion by *Kpn* I and 30 *Sac* I by using the following protocol:

- 37 µl vector (~6 µg)
- 6 µl Multi-Core™ buffer system
- 6 µl BSA
- 2.5 µl *Kpn* I

- 2.5 µl *Sac I*
- 6 µl dH₂O

3 hours incubation was performed at 37°C, digestion was verified with agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

5 The result of enzymatic reaction was evaluated qualitatively and quantitatively by using agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis. Double digested pETM-Adp was isolated by Protocol 2 and isolated linear pETM-Adp was quantified by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

Step 7- Preparation of insert for ligation:

10 GFP coding gene was provided by removing the gene from pGFPuv vector by *Kpn I* and *Sac I* double digestion.

- 56 µl pGFPuv vector (~5.5 µg)
- 8 µl Multi-Core™ buffer system
- 8 µl BSA

15 • 4 µl *Kpn I*
• 4 µl *Sac I*

3 hours incubation was performed at 37°C, quality of digestion was verified and quantity of DNA was estimated by using agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

20 **Step 8- Ligation:**

Linearized (*Kpn I* and *Sac I* double digested) pETM-Adp vector and GFP insert (*Kpn I* and *Sac I* double digested) were ligated using the following protocol with different concentration ratios between the vector and insert:

<u>pETM-Adp +</u> <u>GFP 1:1 (v:v)</u>	<u>PETM-Adp +</u> <u>GFP 1:12 (v:v)</u>	<u>pETM-Adp +</u> <u>GFP 2:0.2 (v:v)</u>	<u>pETM-Adp +</u> <u>GFP 2:2 (v:v)</u>	<u>pETM-Adp</u> <u>Self ligation</u>
1 µl pETM-Adp	1 µl pETM-Adp	1 µl pETM-Adp	2 µl pETM-Adp	1 µl pETM-Adp
1 µl GFP	12 µl GFP	0.2 µl GFP	2 µl GFP	2 µl Ligase Buffer
2 µl Ligase Buffer	2 µl Ligase Buffer	2 µl Ligase Buffer	2 µl Ligase Buffer	1 µl Ligase
1 µl Ligase	1 µl Ligase	1 µl Ligase	1 µl Ligase	16 µl dH ₂ O
15 µl dH ₂ O	4 µl dH ₂ O	14.8 µl dH ₂ O	13 µl dH ₂ O	

Ligations were performed by incubating above ligation mixes at 25°C overnight.

Step 9- Transformation:

- 50 µl competent *E. coli* XL1-Blue cloning strain was added on overnight pETM-Adp + GFP 1:12; 2:0.2; 2:2; self lig. ligation mixes. 50 µl competent *E. coli* BL21-DE3 expression strain was added on overnight pETM-Adp + GFP 1:1. In addition to above indicated tubes, one transformation control (1 µl uncut pETM-Adp, 19 µl dH₂O), one negative control (50 µl untransformed BL21-DE3) and one positive control (50 µl untransformed BL21-DE3) were prepared in different tubes for spreading on different media.
- Competent cell added ligation mixes were incubated 20 min on ice.
- 10 • Tubes were incubated at 42°C heat block for 3 minutes.
- 900 µl LB (without Kanamycin) was added to each ligation mix.
- LB added transformation mixes are incubated for 1.5 hours at 37°C with 190 rpm shaking.
- 100 µl and 400 µl aliquots of pETM-Adp + GFP 1:12; 2:0.2; 2:2; self lig.; negative control and transformation control tube contents were spread on Luria Agar+Kanamycin plates, pETM-Adp + GFP 1:1 tube content was spread on a plate half of which was enriched with 1 mM IPTG before the colony spreading step; positive control was spread on Luria Agar plate and the plates were incubated overnight at 37°C incubator.

20 Step 10: Colony Check for Presence of Insert:

Colonies bearing functional GFP gene was selected by checking fluorescence under UV light source. 3 colonies were picked from both XL1-Blue strain and BL21-DE3 strain containing plates. The picked colonies were grown overnight in 5 mL LB+Kanamycin cultures individually at 37°C with 300 rpm shaking.

25 Next day, pelleted bacterial cultures were photographed under UV for fluorescence; plasmid isolation was performed by application of Protocol 3 to each overnight culture. Each isolated plasmid was digested by both *Sac* I and *Nco* I under the following conditions:

- 3 µl mini-prep isolated plasmid
- 1 µl Multi-Core™ buffer system
- 30 - 1 µl BSA
- 0.5 µl *Sac* I
- 0.5 µl *Nco* I
- 4 µl dH₂O (MilliQ filtered, sterile)
- Incubation for 3 hours at 37°C.

Presence of vector plasmid and presence of insert were detected by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis analysis and quantified by spectroscopic analysis in UV-visible wavelength range.

Step 10a-80 Stock Preparation:

5 After the presence of plasmids with inserts were verified with agarose gel electrophoresis, glycerol stocks of plasmid bearing colonies were prepared by the following protocol:

- To 850 µl overnight grown bacterial culture, 150 µl sterile glycerol was added.
- Mixed by vortexing.
- Frozen in liquid nitrogen.

10 • Kept at -80°C.

Step 11-Expression (Induction of GFP and GFPimm Synthesis):

Starter cultures of GFPuv and GFPimm bearing BL21-DE3 expression strains were grown in 5 mL LB+ Ampicillin (0.1 mg/mL Amp.) and LB+ Kanamycin (0.05 mg/mL Kan.) respectively for 8 hours at 37°C with 300 rpm shaking.

15 Absorbance measurements of cultures were performed at 600 nm and starter cultures were diluted to 0.02 OD in 2x250 mL LB+ Ampicillin (0.1 mg/mL Amp.) and LB+Kanamycin (0.05 mg/mL Kan.) in 2x1000mL Erlenmayer flasks. The cultures were grown overnight at 37°C with 300 rpm shaking.

Step 12-Purification of GFPimm Protein Construct:

20 Purification of GFPimm construct was performed by using Protocol 4 with the exception in scaling up so that 40 mL 1x Native binding buffer was used to resuspend bacterial pellet. Isolated GFP was quantified using spectroscopic analysis for 397 nm wavelength which is characteristic local absorption maximum of GFP. Quantification was verified by Sodium Dodecyl Sulphate – Polyacrylamide gel electrophoresis results.

Step 13-Purification of GFPuv Protein:

40 mL 30 mM Tris-HCl, pH 7.5 + Lysozyme (1 mg/mL) was used to resuspend pelleted bacteria. The bacteria suspension was incubated for 30 min. on ice, then sonicated for 4 min with 10(sec):10(sec) pulse:cooling steps on ice.

Cell debris was precipitated by centrifugation at 17000g for 15 min at 4°C.

30 Soluble phase was filtered through 0.45 and 0.22 µm filters respectively. Filtered solution was applied to MonoQ ion exchange column with a linear salt concentration gradient from degassed, 0.22µm filtered, 30 mM Tris-HCl, pH 7.5 to degassed, 0.22µm filtered, 30 mM Tris-HCl, 1 M NaCl pH 7.5 with 0.5 mL/min flow rate.

Isolated GFP was quantified using spectroscopic analysis for 397 nm wavelength which is characteristic local absorption maximum of GFP. Quantification was verified by Sodium Dodecyl Sulphate – Polyacrylamide gel electrophoresis results.

Step 14-Lowering Na⁺ Concentration for Binding Preparation:

5 GFPuv and GFPimm proteins were dialysed against 25mM Na₃PO₄; 250 mM NaCl with different pH values (pH 6.0, pH 7.0, pH 8.0) for 6 hours at 4°C. GFP samples were then centrifuged in 2 mL Eppendorf tubes and supernatants were taken in clean Eppendorf tubes. Supernatants were re-quantified for GFP content using spectroscopic analysis and SDS-Polyacrylamide gel electrophoresis.

10 **Step 15-Surface Preparation:**

2 M and 3 M ammonium persulfate solutions were prepared (for 3 M APS preparation, solution must be heated to 45°C)

Polystyrene 96 well plate was filled 2/3 of its well capacity providing lanes for dH₂O, 2M APS and 3M APS. The 96 well plate was tightly closed and incubated for 24 hours at 70°C.

15 The plate was rinsed with dH₂O and dried in 70°C.

Note – Infrared spectroscopic evidence given in Figure 6 verified the formation of carboxylic acid functional groups.

Step 16-Binding to Surface:

20 After verifying that impurity of GFPuv and GFPimm proteins are comparable, their concentration was equalized by diluting concentrated sample considering data from spectroscopic analysis.

Fluorescence of empty plate was measured by Molecular Devices: SpectraMax GeminiXS Fluorometer.

25 • 100 µl of GFPuv and GFPimm containing samples were loaded in wells of 96 well plate in an order from pH 6.0 to pH 8.0. Binding was performed with appropriate buffer with the pH of the sample.

- Binding was performed by 2 hours incubation at room temperature.

dH₂O 2M APS mod. 3M APS mod.

Blank for Background			
GFPuv at pH 6	X	X	X
GFPimm at pH 6	X	X	X
GFPuv at pH 7	X	X	X
GFPimm at pH 7	X	X	X
GFPuv at pH 8	X	X	X
GFPimm at pH 8	X	X	X

Step 17-Measurements:

- Samples were removed from wells of plate and the plate was rinsed 3 times with pipetting 200 µl appropriate buffer for each well.
- All the liquid was removed from the wells.

5 • Fluorescence was measured when the plate was dry.

- The wells were filled with 100 µl of appropriate binding buffer and fluorescence measurements were repeated.

Photographs of dry and wet cases for GFP bound plates were taken under UV light.

Life span of the proposed technology is difficult to predict, but it is undeniable that
10 molecular biology has become an irrevocable part of the basic sciences and therefore a potential market for protein products is unrelenting. Areas of use or application may be analysis, incubation, storage, catalysis, stabilisation, binding, purification, scavenging and immobilisation of bio-polymers.

Any industry based on protein expression, protein technology, medicine, or specialty
15 plastics and glasses could realise profit following implementation of this process.

Applicants are also exploring secondary applications that might exploit the physico-chemical properties of this system.

REFERENCES

Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol. 135 (K. Mosbach, Ed) Academic Press, 1987, NY,

Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol.137 (K. Mosbach, Ed) Academic Press, 1988, NY;

Immobilisation of enzymes and cells (GF Bickerstaff, Ed.) Humana Press, 1997, NJ, USA,

Immobilised biomolecules In analysis: A practical approach (T Cass and FS Ligler, Eds) Oxford University Press, 1998, NY.

S. Nock, J.A Spudich and P. Wagner (1997) "Reversible, site-specific immobilisation of polyarginine-tagged fusion proteins on mica surfaces" FEBS Letters 141, 233-238)

B Jonsson, B Lindman, k. Holmberg and B Kronberg, Interaction of Polymers with Surfaces: in surfactant and polymers in aqueous solution, John Wiley and Sons, 1998, NY.

G.P. Royer (1974) Supports for immobilized enzymes, CHEMTECH 4, 699

Y Harada, K Yasuda, S Nomura, n Kajimura and Y C Sasaki (1998) Vectorially Oriented Fixation of Membrane-Embedded Bacteriorhodopsin onto an Inert Base" Langmuir 14, 1829-1835.

Inouye, S et al. "Aequorea green fluorescent protein: Expression of the gene and fluorescence characteristics of the recombinant protein" FEBS Letters 341 (1994) pages 227-280.

Dyke, Michael W. Van; Sirito, Maro and Sawadogo, Michèle "Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain", Gene, Col.111, Issue 1, 1 Feb. 1992, pages 99-104.

Green fluorescent protein: properties, applications and protocols (m Chalfie, S kain, Eds.) Wiley-Liss, 1998, NY;

Protein localisation by fluorescence microscopy: a practical approach (VJ Allan, Ed.) Oxford University Press, 2000, NY; Imprint oxford; New York: Oxford University Press, c2000; Oancea, Diacylglycerol Signalling in Living Cells "The Journal of Cell Biology, Volume 140, No.3,

E et al "Green Fluorescent Protein (GFP)-tagged Cysteine-rich Domains from protein Kinase Cas Fluorescent Indications for February 9, 1998, pages 485-498.

J Sambrook and D W Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.

PROTOCOL 1
Plasmid or Cosmid DNA Purification Using
QIAGEN® Plasmid Midi and Maxi Kits

Things to do before starting

- 5 • Add the provided RNase A solution to Buffer P1 before use. Use one vial of RNase A (spin down briefly before use) per bottle of Buffer P1, to give a final concentration of 100 µg/ml.
 • Check Buffer P2 for SDS precipitation due to low storage temperatures.
 If necessary, dissolve the SDS by warming to 37°C.
- 10 • Pre-chill Buffer P3 to 4°C.

Procedure

1. Pick a single colony from a freshly streaked selective plate and inoculate a starter culture of 2–5 ml LB medium containing the appropriate selective antibiotic. Incubate for ~8 h at 37°C with vigorous shaking (~300 rpm).
- 15 2. Dilute the starter culture 1/500 to 1/1000 into selective LB medium. For high-copy plasmids inoculate 25 ml medium. For low-copy plasmids, inoculate 100 ml medium. Grow at 37°C for 12–16 h with vigorous shaking (~300 rpm).
3. Harvest the bacterial cells by centrifugation at 6000 x g for 15 min at 4°C.
4. Resuspend the bacterial pellet in 4 ml of Buffer P1.
- 20 5. Add 4 ml of Buffer P2, mix gently but thoroughly by inverting 4–6 times, and incubate at room temperature for 5 min. Do not vortex, as this will result in shearing of genomic DNA. The lysate should appear viscous. Do not allow the lysis reaction to proceed for more than 5 min. After use, the bottle containing Buffer P2 should be closed immediately to avoid acidification from CO₂ in the air.
- 25 6. Add 4 ml of chilled Buffer P3, mix immediately but gently by inverting 4–6 times, and incubate on ice for 15 min or 20 min.
7. Centrifuge at 20,000 x g for 30 min at 4°C. Remove supernatant containing plasmid DNA promptly. After centrifugation the supernatant should be clear.
8. Centrifuge the supernatant again at 20,000 x g for 15 min at 4°C. Remove supernatant containing plasmid DNA promptly.
- 30 9. Equilibrate a QIAGEN-tip 100 by applying 4 ml Buffer QBT, and allow the column to empty by gravity flow. Allow the QIAGEN-tip to drain completely.
10. Apply the supernatant from step 8 to the QIAGEN-tip and allow it to enter the resin by gravity flow.

11. Wash the QIAGEN-tip with 2 x 10 ml Buffer QC. Allow Buffer QC to move through the QIAGEN-tip by gravity flow.
12. Elute DNA with 5 ml Buffer QF. Collect the eluate in a 10 ml or 30 ml tube. Use of polycarbonate centrifuge tubes is not recommended as polycarbonate is not resistant to the
5 alcohol used in subsequent steps. If you wish to stop the protocol and continue later, store the eluate at 4°C. Storage periods longer than overnight are not recommended.
13. Precipitate DNA by adding 3.5 ml room-temperature isopropanol to the eluted DNA. Mix and centrifuge immediately at 15,000 x g for 30 min at 4°C. Carefully decant the supernatant. All solutions should be at room temperature in order to minimize salt
10 precipitation, although centrifugation is carried out at 4°C to prevent overheating of the sample. Isopropanol pellets have a glassy appearance and may be more difficult to see than the fluffy, salt-containing pellets that result from ethanol precipitation. Marking the outside of the tube before centrifugation allows the pellet to be more easily located. Isopropanol pellets are also more loosely attached to the side of the tube, and care should
15 be taken when removing the supernatant.
14. Wash DNA pellet with 2 ml of room-temperature 70% ethanol, and centrifuge at 15,000 x g for 10 min. Carefully decant the supernatant without disturbing the pellet. The 70% ethanol removes precipitated salt and replaces isopropanol with the more volatile ethanol, making the DNA easier to redissolve.
20. 15. Air-dry the pellet for 5–10 min, and redissolve the DNA in a suitable volume of buffer (e.g., TE buffer, pH 8.0, or 10 mM Tris·Cl, pH 8.5). Redissolve the DNA pellet by rinsing the walls to recover all the DNA, especially if glass tubes have been used. Pipetting the DNA up and down to promote resuspension may cause shearing and should be avoided. Overdrying the pellet will make the DNA difficult to redissolve. DNA dissolves best under
25 slightly alkaline conditions; it does not easily dissolve in acidic buffers.

Determination of yield: To determine the yield, DNA concentration should be determined by both UV spectrophotometry and quantitative analysis on an agarose gel.

PROTOCOL 2**QIAquick Gel Extraction Kit Protocol using a microcentrifuge**

This protocol is designed to extract and purify DNA of 70 bp to 10 kb from standard or low-melt agarose gels in TAE or TBE buffer. Up to 400 mg agarose can be processed per spin column.

Notes: The yellow color of Buffer QG indicates a pH ~7.5.

- 5 • Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume).
 • Isopropanol (100%) and a heating block or water bath at 50°C are required.
 • All centrifugation steps are carried out at 13,000 rpm (~17,900 x g) in a conventional table-top microcentrifuge.
 • 3 M sodium acetate, pH 5.0, may be necessary.
- 10 1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel. Minimize the size of the gel slice by removing extra agarose.

 2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of gel (100 mg ~ 100 µl). The maximum amount of gel slice per QIAquick column is 400 mg; for gel slices >400 mg use more than one QIAquick column.
- 15 3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To help dissolve gel, mix by vortexing the tube every 2–3 min during the incubation. IMPORTANT: Solubilize agarose completely.

 4. After the gel slice has dissolved completely, check that the color of the mixture is yellow (similar to Buffer QG without dissolved agarose). If the color of the mixture is orange or violet, add 10 µl of 3 M sodium acetate, pH 5.0, and mix. The color of the mixture will turn to yellow. The adsorption of DNA to the QIAquick membrane is efficient only at pH ~7.5. Buffer QG contains a pH indicator which is yellow at pH ~7.5 and orange or violet at higher pH, allowing easy determination of the optimal pH for DNA binding.
- 20 5. Add 1 gel volume of isopropanol to the sample and mix. This step increases the yield of DNA fragments <500 bp and >4 kb. For DNA fragments between 500 bp and 4 kb, addition of isopropanol has no effect on yield. Do not centrifuge the sample at this stage.
- 25 6. Place a QIAquick spin column in a provided 2 ml collection tube.

 7. To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min. The maximum volume of the column reservoir is 800 µl. For sample volumes of more
- 30 than 800 µl, simply load and spin again.

 8. Discard flow-through and place QIAquick column back in the same collection tube. Collection tubes are re-used to reduce plastic waste.

9. (Optional): Add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min. This step will remove all traces of agarose. It is only required when the DNA will subsequently be used for direct sequencing, in vitro transcription or microinjection.
10. To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min. Note: If the DNA will be used for salt sensitive applications, such as blunt-end ligation and direct sequencing, let the column stand 2–5 min after addition of Buffer PE, before centrifuging.
11. Discard the flow-through and centrifuge the QIAquick column for an additional 1 min at 13,000 rpm (~17,900 × g). IMPORTANT: Residual ethanol from Buffer PE will not be completely removed unless the flow-through is discarded before this additional centrifugation.
12. Place QIAquick column into a clean 1.5 ml microcentrifuge tube.
13. To elute DNA, add 50 µl of Buffer EB (10 mM Tris·Cl, pH 8.5) or H₂O to the center of the QIAquick membrane and centrifuge the column for 1 min. Alternatively, for increased DNA concentration, add 30 µl elution buffer to the center of the QIAquick membrane, let the column stand for 1 min, and then centrifuge for 1 min.
14. IMPORTANT: Ensure that the elution buffer is dispensed directly onto the QIAquick membrane for complete elution of bound DNA. The average eluate volume is 48 µl from 50 µl elution buffer volume, and 28 µl from 30 µl.
15. Elution efficiency is dependent on pH. The maximum elution efficiency is achieved between pH 7.0 and 8.5. When using water, make sure that the pH value is within this range, and store DNA at –20°C as DNA may degrade in the absence of a buffering agent. The purified DNA can also be eluted in TE (10 mM Tris·Cl, 1 mM EDTA, pH 8.0), but the EDTA may inhibit subsequent enzymatic reactions.

PROTOCOL 3

QIAprep Spin Miniprep Kit Protocol using a microcentrifuge

This protocol is designed for purification of up to 20 µg of high-copy plasmid DNA from 1–5 ml overnight cultures of *E. coli* in LB (Luria-Bertani) medium.

5 All protocol steps should be carried out at room temperature.

Procedure

1. Resuspend pelleted bacterial cells in 250 µl Buffer P1 and transfer to a microcentrifuge tube. Ensure that RNase A has been added to Buffer P1. No cell clumps should be visible after resuspension of the pellet.
- 10 2. Add 250 µl Buffer P2 and gently invert the tube 4–6 times to mix. Do not vortex, as this will result in shearing of genomic DNA. Do not allow the lysis reaction to proceed for more than 5 min.
- 15 3. Add 350 µl Buffer N3 and invert the tube immediately but gently 4–6 times. To avoid localized precipitation, mix the solution gently but thoroughly, immediately after addition of Buffer N3. The solution should become cloudy.
4. Centrifuge for 10 min at maximum speed in a tabletop microcentrifuge.
5. Apply the supernatants from step 4 to the QIAprep column by decanting or pipetting.
6. Centrifuge for 30–60 s. Discard the flow-through.
7. (Optional): Wash the QIAprep spin column by adding 0.5 ml Buffer PB and centrifuging for 30–60 s. Discard the flow-through. This step is necessary to remove trace nuclease activity when using *endA+* strains such as the JM series, HB101 and its derivatives, or any wild-type strain, which have high levels of nuclease activity or high carbohydrate content.
- 20 8. Wash QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging for 30–60 seconds.
- 25 9. Discard the flow-through, and centrifuge for an additional 1 min to remove residual wash buffer. IMPORTANT: Residual wash buffer will not be completely removed unless the flow-through is discarded before this additional centrifugation. Residual ethanol from Buffer PE may inhibit subsequent enzymatic reactions.
- 30 10. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA, add 50 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water to the center of each QIAprep column, let stand for 1 min, and centrifuge for 1 min.

PROTOCOL 4
ProBond Purification System
A manual of methods for purification of
polyhistidine-containing recombinant proteins

ProBond resin should be stored at +4°C. All other components of the protocol may be stored at room temperature.

Additional Materials: All native purification buffers are prepared from the 5X Native Purification Buffer (250 mM Na₃PO₄; 2.5 M NaCl) and the 3 M Imidazole.

5 Resin and Column Specifications: ProBond resin is precharged with Ni²⁺ ions and appears blue in color. It is provided as a 50% slurry in 20% ethanol. Binding capacity of ProBond resin: 1.5 mg of protein per ml of resin, Recommended flow rate: 0.5 ml/min. pH stability (long term): 3.13, pH stability (short term): 2.14

10 Binding Characteristics: ProBond® resin uses the chelating ligand iminodiacetic acid (IDA) in a highly cross-linked agarose matrix. IDA binds Ni²⁺ ions by three coordination sites.

Preparation of Native Purification Buffers

You must dilute and adjust the pH of the 5X Native Purification Buffer to create 1X Native Purification Buffer (50 mM Na₃PO₄; 500 mM NaCl; pH 8.0). From this, you can create the following buffers: Native Binding Buffer, Native Wash Buffer, Native Elution Buffer.

15 To prepare the native buffers, you will need the following reagents:

5X Native Purification Buffer, 3M Imidazole, NaOH, HCl, Sterile distilled water.

20 **Imidazole Concentration in Native Buffers:** Imidazole is included in the native wash and elution buffers to minimize the binding of untagged, contaminating proteins and increase the purity of the target protein with fewer wash steps. Note that, if your level of contaminating proteins is high, imidazole can also be added to the native binding buffer. If your protein does not bind well under these conditions, you can experiment with lowering or eliminating the concentration of imidazole in the buffers and increasing the number of wash and elution steps.

25 **1X Native Purification Buffer:** For the following recipes, you must dilute and adjust the pH of the 5X Native Purification Buffer (supplied in the kit) to create 1X Native Purification Buffer. To prepare 100 ml of 1X Native Purification Buffer, combine: 80 ml of H₂O, 20 ml of 5X Native Purification Buffer. Adjust pH to 8.0 with NaOH or HCl

Native Binding Buffer Without Imidazole: Reserve 30 ml of the 1X Native Purification Buffer for use as the Native Binding Buffer (for column preparation, cell lysis, and binding).

Native Wash Buffer: To prepare 50 ml of Native Wash Buffer with 20 mM imidazole, combine; 50 ml of 1X Native Purification Buffer, 335 μ l of 3M Imidazole. Adjust pH to 8.0 with NaOH or HCl.

5 Native Elution Buffer: To prepare 15 ml of Native Elution Buffer with 250 mM imidazole, combine: 13.75 ml of 1X Native Purification Buffer, 1.25 ml of 3M Imidazole. Adjust pH to 8.0 with NaOH or HCl.

10 Preparation of the ProBond Columns: Do not use strong reducing agents such as DTT with ProBond[®] columns. DTT reduces the nickel ions in the resin. In addition, do not use strong chelating agents such as EDTA or EGTA in the loading buffers or wash buffers, as these will strip the nickel from the columns. Be sure to check the pH of your buffers before starting

Column Preparation: When preparing a column as described below, make sure that the snap-off cap at the bottom of the column remains intact. To prepare a column:

1. Resuspend the ProBond[®] resin in its bottle by inverting and gently tapping the bottle repeatedly.
- 15 2. Pipet or pour 2 ml of the resin into a 10-ml Purification Column (Scale up the resin amount if necessary, considering the binding capacity of ProBond resin. All following steps are written for 2mL resin volume). Gently pellet it by low-speed centrifugation (1 minute at 800 x g). Gently aspirate the supernatant. Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the column. Pipet or pour 2 ml of the resin into a 10-ml Purification Column. Gently pellet it by low-speed centrifugation (1 minute at 800 x g). Gently aspirate the supernatant.
- 20 3. Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the column.
4. Repellet the resin using centrifugation as described in Step 2, and gently aspirate the supernatant.
- 25 5. For purification under Native Conditions, add 6 ml of Native Binding Buffer (see the recipe on previous page).
6. Resuspend the resin by alternately inverting and gently tapping the column.
- 30 7. Repellet the resin using centrifugation as described in Step 2, and gently aspirate the supernatant.
8. Repeat Steps 5 through 7.

Storing Prepared Columns: To store a column containing resin, add or 20% ethanol as a preservative and cap or parafilm the column. Store at room temperature.

Preparation of Bacteria Cell Lysate in Native Conditions

Follow the procedure below to prepare bacteria cell lysate under native conditions. Scale up or down as necessary.

- 5 1. Harvest cells from a 50 ml culture by centrifugation (e.g., 5000 rpm for 5 minutes in a Sorvall SS-34 rotor). Resuspend the cells in 8 ml of Native Binding Buffer.
2. Add 8 mg of lysozyme and incubate on ice for 30 minutes.
3. Using a sonicator equipped with a microtip, sonicate the solution on ice using six 10-second bursts at high intensity with a 10-second cooling period between each burst.
- 10 4. Centrifuge the lysate at 3,000 x g for 15 min to pellet the cellular debris. Transfer the supernatant to a fresh tube.
5. Store the lysate on ice or freeze at -20° C. Save 20 µl of the lysate at +4° C for SDS-PAGE analysis

15 Introduction

In the following procedure, use the prepared Native Wash Buffer and Native Elution Buffer and the columns and cell lysate prepared under native conditions. Be sure to check the pH of your buffers before starting.

Purification Under Native Conditions

- 20 1. Add 8 ml of lysate to a prepared Purification Column.
2. Bind for 30-60 minutes using gentle agitation to keep the resin suspended in the lysate solution.
- 25 3. Settle the resin by low speed centrifugation (800 x g), and carefully aspirate the supernatant. Save supernatant at +4° C for SDS-PAGE analysis.
4. Wash with 8 ml Native Wash Buffer. Settle the resin by gravity or low speed centrifugation (800 x g), and carefully aspirate the supernatant. Save supernatant at +4° C for SDS-PAGE analysis.
- 30 5. Repeat Step 4 three more times.
6. Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with 8-12 ml Native Elution Buffer. Collect 0.5 or 1 ml fractions and analyze with SDS-PAGE.

6. Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with 8-12 ml Native Elution Buffer. Collect 0.5 or 1 ml fractions and analyze with SDS-PAGE.

Note: Elution fractions should be stored at +4° C. If -20° C storage is required, glycerol
5 should be added to the fraction. For long term storage, protease inhibitors can be added.

Recharging ProBond® Resin

ProBond® resin can be used for up to three or four purifications of the same protein without recharging. We recommend not recharging the resin more than three times and only reusing it for purification of the same recombinant protein.

10 To recharge 2 ml of resin in a purification column:

1. Wash the column two times with 8 ml of 50 mM EDTA to strip away the chelated nickel ions.

2. Wash the column two times with 8 ml of 0.5M NaOH.

3. Wash the column two times with 8 ml of sterile, distilled water.

15 4. Recharge the column with two washes of 8 ml NiCl₂ hexahydrate at a concentration of 5 mg/ml prepared in sterile, distilled water.

5. Wash the column two times with 8 ml of distilled water.

6. Add 20% ethanol as a preservative and cap or parafilm the column. Store at room temperature.

SEQUENCE LISTING 1

1 GGTACCGGTA GAAAAAATGA GTAAAGGAGA AGAACCTTTC ACTGGAGTTG
51 TCCCAATTCT TGTTGAATTA GATGGTGATG TTAATGGGCA CAAATTTCT
101 GTCAGTGGAG AGGGTGAAGG TGATGCAACA TACGGAAAAC TTACCCTTAA
5 151 ATTTATTTGC ACTACTGGAA AACTACCTGT TCCATGGCCA ACACTTGTCA
201 CTACTTTCTC TTATGGTGT CAATGCTTT CCCGTTATCC GGATCATATG
251 AACACGGCATG ACTTTTCAA GACTGCCATG CCCGAAGGTT ATGTACAGGA
301 ACGCACTATA TCTTTCAAAG ATGACGGGAA CTACAAGACG CGTGCTGAAG
351 TCAAGTTGA AGGTGATACC CTTGTTAACATC GTATCGAGTT AAAAGGTATT
10 401 GATTTAAAG AAGATGGAAA CATTCTCGGA CACAAACTCG AGTACAAC TA
451 TAACTCACAC AATGTATACA TCACGGCAGA CAAACAAAAG AATGGAATCA
501 AAGCTAACCTT CAAAATTGCG CACAACATTG AAGATGGATC CGTTCAACTA
551 GCAGACCATT ATCAACAAAA TACTCCAATT GGCATGGCC CTGTCCTTT
601 ACCAGACAAC CATTACCTGT CGACACAATC TGCCCTTCG AAAGATCCCA
15 651 ACGAAAAGCG TGACCACATG GTCCTTCTTG AGTTTGTAAAC TGCTGCTGGG
701 ATTACACATG GCATGGATGA GCTCTACAAA TAA

SEQUENCE LISTING 2

1	CATCACCATC	ACCATCACCC	CATGAGCGAT	TACGACATCC	CCACTACTGA
51	GAATCTTAT	TTTCAGGGCG	CCATGGCGGC	GGCGGTTCGG	ATGAACATCC
101	AGATGCTGCT	GGAGGGGGCC	GACTATCTGG	AGCGGGGGGA	GAGAGAAGCT
151	GAACATGGTT	ATGCCCTCCAT	GTTACCATAAC	AAAAACAAGG	ACAGAGATGC
201	CTTAAAACGG	AGGAACAAAT	CCAAAAAGAA	TAACAGCGAT	AGCAGATCAA
251	CTCACAAATGA	AATGGAGAAG	AATAGACGGG	CTCATCTTCG	CTTGTGCCTG
301	GAGAAGTTGA	AGGGGCTGGT	GCCACTGGGA	CCCAGATCAA	GTCGACACAC
351	TACGGTGAAGT	TTATTAAACAA	AAGCCAAATT	GCACATAAAG	AAACTTGAAAG
401	ATTGTGACAG	AAAAGCCGTT	CACCAAATCG	ACCAGCTTCA	GCGAGAGCAG
451	CGACACCTGA	AGAGGCAGCT	GGAGAACGCT	GGCATTGAGA	GGATCCGGAT
501	GGACAGCATIC	GGCTCCACCG	TCTCCTCGGA	GCGCTCCGAC	TCCGACAGGG
551	AAGAAATCGA	CGTTGACGTG	GAGAGCACGG	ACTATCTCAC	AGGTGATCTG
601	GACTGGAGCA	GCAGCAGCTG	GAGCAGACTCT	GACGAGCGGG	GCAGCATGCA
651	GAGCCTCGGC	AGTGTGAGG	GCTATTCCAG	CACCAGCATC	AAGAGAATAA
701	AGCTGCAGGA	CAGTCACAAG	CCGTGTCTTG	GTCTCTAACT	AGTGGTACCG
751	GATCCGAATT	CGAGCTCCGT	CGACAAGCTT	GCGGCCGCAC	TCGAGCACCA
801	CCACCACCAAC	CACTGAGATC	CGGCTGCTAA	CAAAGCCCAG	AAGGAAGCTG
851	AGTTGGCTGC	TGCCACCGCT	GAGCAATAAC	TAGCATAACC	CCTTGGGGCC
901	TCTAAACGGG	TCTTGAGGGG	TTTTTGCTG	AAAGGAGGAA	CTATATCCGG
951	ATTGGCGAAT	GGGACCGCAGC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGGTGT
1001	GGTGGTTACG	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCCG
1051	CTCCTTCCG	TTTCTCCCT	TCCCTTCTCG	CCACGTTCGC	CGGCTTTCCC
1101	CGTGTAGCTC	AAATCGGGG	GACTCCCTTA	GGGTTCCGAT	TTAGTGTCTT
1151	ACGGCACCTC	GACCCCCAAA	AACTTGATTA	GGGTGATGGT	TCACGTAGTG
1201	GGCCATCGCC	CTGATAGACG	TTTTTCGCGC	CTTGTACGTT	GGAGTCCACG
1251	TTCTTTAATA	GTGGACTCTT	GTTCCTAAACT	GGAACAAACAC	TCAACCTAT
1301	CTCGGTCTAT	TCTTTGATT	TATAAGGGAT	TTTGCCTGATT	TCGGCCTATT
1351	GGTTAAAAAA	TGAGCTGATT	TAACAAAAAT	TTAACCGGAA	TTTTAACAAA
1401	ATATTAACGT	TTACAATTTC	AGGTGGCACT	TTTCGGGGAA	ATGTGCGCGG
1451	AACCCCTATT	TGTTTATTTT	TCTAAATACA	TTCAAATATG	TATCCGCTCA
1501	TGAATTAAATT	CTTAGAAAAAA	CTCATCGAGC	ATCAAATGAA	ACTGCAATT
1551	ATTCAATATCA	GGATTATCAA	TACCATATT	TTGAAAAAGC	CGTTCTGTA
1601	ATGAAGGAGA	AAACTCACCG	AGGCAGTTCC	ATAGGATGGC	AAGATCCTGG
1651	TATCGGTCTG	CGATTCCGAC	TCGTCCAACA	TCATAACAAAC	CTATTAATT
1701	CCCCTCGTCA	AAAATAAGGT	TATCAAGTG	GAAATCACCA	TGAGTGACGA
1751	CTGAATCCGG	TGAGAATGGC	AAAAGTTTAT	GCATTCTTT	CCAGACTTGT
1801	TCAACAGGCC	AGCCATTACG	CTCGTCATCA	AAATCACTCG	CATCAACCAA
1851	ACCGTTATTC	ATTCTGTGATT	GCGCCTGAGC	GAGACGAAAT	ACCGGATCGC
1901	TGTTAAAAGG	ACAATTACAA	ACAGGAATCG	AATGCAACCG	GCGCAGGAAC
1951	ACTGCCAGCG	CATCAACAAT	ATTTTCACCT	GAATCAGGAT	ATTCTTCTAA
2001	TACCTGGAAT	GCTGTTTCC	CGGGGATCGC	AGTGGTGAGT	AACCATGCTAT
2051	CATCAGGAGT	ACGGATAAAA	TGCTTGATGG	TCGGAAGAGG	CATAAATTCC
2101	GTCAGCGAGT	TTAGTCTGAC	CATCTCATCT	GTAACATCAT	TGGCAACGCT
2151	ACCTTTGCCA	TGTTTCAGAA	ACAACTCTGG	CCGATCGGGC	TTCCCACATACA
2201	ATCGATAGAT	TGTCGACACT	GATTGCCGGA	CATTATCGCG	AGCCCATTTA
2251	TACCCATATA	AATCAGCATC	CATGTTGGAA	TTAACATCGCG	GCCTAGAGCA
2301	AGACGTTTCC	CGTTGAATAT	GGCTCATAAC	ACCCCTGT	TTACTGTTA
2351	TGTAAGCAGA	CAGTTTATT	GTTCATGACC	AAAATCCCTT	AACGTGAGTT
2401	TTCGTTCCAC	TGAGCGTCAG	ACCCCGTAGA	AAAGATCAA	GGATCTTCTT
2451	GAGATCCTT	TTTCTGCGC	GTAATCTGCT	GCTTGCACAC	AAAAAAACCA
2501	CCGCTACCAAG	CGGTGGTTTG	TTTGCCGGAT	CAAGAGCTAC	CAACTCTTT
2551	TCCGAAGGTA	ACTGGCTTCA	GCAGAGCGCA	GATACCAAAT	ACTGCTCTC
2601	TAGTGTAGCC	GTAGTGTAGGC	CACCACTTC	AGAACTCTGT	AGCACCGCCT
2651	ACATACCTCG	CTCTGCTAAAT	CCTGTTACCA	GTGGCTGCTG	CCAGTGGCGA
2701	TAAGTCGTGT	CTTACCGGGT	TGGACTCAAG	ACGATAGTTA	CCGGATAAGG
2751	CGCAGCGGTG	GGGCTGAAACG	GGGGGTTCGT	GCACACAGCC	CAGCTTGGAG
2801	CGAACGACCT	ACACCGAAACT	GAGATAACCTA	CAGCGTGAGC	TATGAGAAAG
2851	CGCCACGCTT	CCCGAAGGGG	GAAAGGCGGA	CAGGTATCCG	GTAAGCGGGCA
2901	GGGTCGGAAC	AGGAGAGCGC	ACGAGGGAGC	TTCCAGGGGG	AAACGCCTGG
2951	TATCTTTATA	GTCCTGTCGG	GTTCGCCCCAC	CTCTGACTTG	AGCGTCGATT

	3001	TTTGTGATGC	TCGTCAGGGG	GGCGGAGGCC	ATGGAAAAAC	GCCAGCAACG
	3051	CGGCCTTTT	ACGGTTCCTG	GCCTTTGCT	GGCCTTTGC	TCACATGTTC
	3101	TTCCCTGCGT	TATCCCCTGA	TTCTGTGGAT	AACCGTATTAA	CCGCCTTGAGA
5	3151	GTGAGCTGAT	ACCGCTCGCC	GCAGCCGAAC	GACCGAGCGC	AGCGAGTCAG
	3201	TGAGCGAGGA	AGCGGAAGAG	CGCCTGATGC	GGTATTTCT	CCTTACGCAT
	3251	CTGTGCGGTA	TTTCACACCG	CATATATGGT	GCACTCTCAG	TACAATCTGC
	3301	TCTGATGCCG	CATA GTTAAG	CCAGTATACA	CTCCGCTATC	GCTACGTGAC
	3351	TGGGTCATGG	CTCGGCCCG	ACACCCGCCA	ACACCCGCTG	ACGCGCCCTG
	3401	ACGGGCTGT	CTGCTCCCGG	CATCCGCTTA	CAGACAAGCT	GTGACCGTCT
10	3451	CCGGGAGCTG	CATGTGTCAG	AGGTTTCAC	CGTCATCACC	GAAACGCGCG
	3501	AGGCAGCTGC	GGTAAAGCTC	ATCAGCGTGG	TCG TGAAGCG	ATTCA CACAGAT
	3551	GTCTGCCGTG	TCATCCGCGT	CCAGCTCGTT	GAGTTCTCC	AGAACCGCTTA
	3601	ATGTCTGGT	TCTGATAAAG	CGGGCCATGT	TAAGGGCGGT	TTTTCCCTGT
	3651	TTGGTCATG	ATGCCCTCGT	GTAAAGGGGA	TTCTGTTC	TGGGGGTAAAT
15	3701	GATACCGATG	AAACGAGAGA	GGATGCTAC	GATACGGTT	ACTGATGATG
	3751	AAACATGCCCG	GTTACTGGAA	CGTTGTGAGG	GTAAACA ACT	GGCGGTATGG
	3801	ATGC GCGGG	ACCA GAGAAA	AATCACTCAG	GGTCAATGCC	AGCGCTTCGT
	3851	TAATACAGAT	GTAGGTGTT	CACAGGGTAG	CCAGCAGCAT	CCTGCGATGC
	3901	AGATCCGAA	CATAATGGTG	CAGGGCGCTG	ACTTCCGCGT	TTCCAGACTT
20	3951	TACGAAACAC	GGAAACCGAA	GACCATT CAT	GTTGTTGCTC	AGGTCGCAGA
	4001	CGTTTTGCAG	CAGCAGTCGC	TTCACGTT	CTCGCGTATC	GGTGATT CAT
	4051	TCTGCTAAC	AGTAAGGCAA	CCCCGCCAGC	CTAGGCCGGT	CCTCAACGAC
	4101	AGGAGCACGA	TCATGCGC AC	CCGTGGGCC	GCCATGCCGG	CGATAATGGC
	4151	CTGCTTCCTCG	CCGAAACGTT	TGGTGGCCGG	ACCAGT GACG	AAGGCTTGAG
25	4201	CGAGGGCGT	CAAGATTCCG	AATACCGCAA	GCGACAGGCC	GATCATCGTC
	4251	GCGCTCCAGC	GAAAGCGGT	CTCGCCGAAA	ATGACCCAGA	GCGCTGCCGG
	4301	CACCTGCTCT	ACGAGTTGCA	TGATAAAAGAA	GACAGTCATA	AGTGC GGGCA
	4351	CGATAGTCAT	GCCCCGCGCC	CACCGGAAGG	AGCTGACTGG	GTTGAAGGCT
	4401	CTCAAGGGCA	TCGGTCGAGA	TCCCCGTG	TAATGAGTGA	GCTAACTTAC
30	4451	ATTAATTGCG	TTGCGCTCAC	TGCCC GCTT	CCAGTCGGGA	AACCTGTCGT
	4501	GCCAGCTGCA	TTAATGAATC	GGCCAACCGC	CGGGGAGAGG	CGGTTTGC GT
	4551	ATTGGCGCC	AGGGTGGTT	TTCTTTAC	CAGT GAGACG	GGCAACAGCT
	4601	GATTGCCCTT	CACCGCCTGG	CCCTGAGAGA	GTTG CAGCAA	CGGGTCCACG
	4651	CTGGTTTGCC	CCAGCAGGCC	AAAATCCTGT	TTGATGGTGG	TTAACGGCGG
35	4701	GATATAACAT	GAGCTGTC	CGGTATCGTC	GTATCCC ACT	ACCGAGATAT
	4751	CCGCACCAAC	GCCGAGCGC	GACTCGTAA	TGGCGCGCAT	TGC GCCCAGC
	4801	GCCATCTGAT	CGTGGCAAC	CAGCATCGCA	GTGGGAACGA	TGCCCTCATT
	4851	CAGCATTTGC	ATGGTTTGT	AAAACCGGA	CATGGCACTC	CAGTCGCC TT
	4901	CCC GTTCCGC	TATCGGCTGA	ATT TGATTG	GAGT GAGATA	TTTATGCCAG
40	4951	CCAGCCAGAC	GCAGACGCGC	CGAGACAGAA	CTTAATGGGC	CCGCTAACAG
	5001	CGCGATTG	TGGTGACCCA	ATGCGACCAG	ATGCTCCACG	CCCAGTCGCG
	5051	TACCGTCTTC	ATGGGAGAAA	ATAATACTGT	TGATGGGTGT	CTGGTCAGAG
	5101	ACATCAAGAA	ATAACGCCGG	AAACATTAGT	CAGGCAGCTT	CCACAGCAAT
	5151	GGCATCTGG	TCATCCAGCG	GATAGTTAAT	GATCAGCCCA	CTGACGCGTT
45	5201	GCGCGAGAAG	ATTGTGCA	GCGCTTAC	AGGCTTCGAC	GCCGCITCGT
	5251	TCTACCATCG	ACACCACAC	GCTGGCACCC	AGTTGATCGG	CGCGAGATTT
	5301	AATCGCCGCG	ACAATTGCG	ACGGCGCGT	CAGGGCCAGA	CTGGAGGTGG
	5351	CAACGCCAAT	CAGCAACGAC	TGTTTGC	CCAGTTGTTG	TGCCACGCC
	5401	TTGGGAATGT	AATT CAGCTC	CGCCATCGCC	GCTTCCACTT	TTTCCCGCGT
50	5451	TTTCGCAGAA	ACGTGGCTGG	CCTGGTAC	CACGCCGGAA	ACGGTCTGAT
	5501	AAGAGACACC	GGCATACTCT	GCGACATCGT	ATAACGTTAC	TGGTTTCACA
	5551	TTCACCACCC	TGAATTGACT	CTCTTCCGG	CGCTATCATG	CCATACC CGCG
	5601	AAAGGTTTG	CGCCATT CGA	TGGTGTCCGG	GATCTCGACG	CTCTCCCTTA
	5651	TGCGACTCCT	GCATTAGGA	GCAGCCCA GT	AGTAGGTTGA	GGCGTGTGAG
55	5701	CACCGCCGCG	GCAAGGAATG	GTGCATGCA	GGAGATGGCG	CCCAACAGTC
	5751	CCCCGGCCAC	GGGGCCTGCC	ACCATACCA	CGCCGAAACAA	AGCGCTCATG
	5801	AGCCC GAAGT	GGCGAGCCG	ATCTTCCCA	TCGGTGTATGT	CGGCGATATA
	5851	GGCGCCAGCA	ACCGCACCTG	TGGCGCCGGT	GATGCCGGCC	ACGATGCGTC
	5901	CGGC GTAGAG	GATCGAGATC	TCGATCCCG	GAAATTAAATA	CGACTCACTA
60	5951	TAGGGAAATT	GTGAGCGGAT	AA CAATT CCC	CTCTAGAAAT	AATTTGATT
	6001	TAAC TTAAG	AAGGAGATAT	ACCATGAAA		

SEQUENCE LISTING 3

1 CATCACCATC ACCATCACCC CATGAGCGAT TAGACATCC CCACTACTGA
 51 GAATCTTAT TTTCAAGGGCG CCATGGGAGG CACGGTACCG GATCCGAATT
 101 CGAGCTCCGT CGACAAGCTT GCAGGCCAC TCGAGCACCA CCACCAC
 5 151 CACTGAGATC CGGCTGCTAA CAAAGCCCAG AAGGAAGCTG AGTTGGCTGC
 201 TGCCACCGCT GAGCAATAAC TAGCATAACC CCTTGGGGCC TCTAAACGGG
 251 TCTTGAGGGG TTTTTGCTG AAAGGAGGAA CTATATCCGG ATTGGCGAAT
 301 GGGACCGGCC CTGTAGCGGC GCATTAAGCG CGCGGGGTGT GGTGGTTACG
 351 CGCAGCGTGA CGCCTACACT TGCCAGCGCC CTAGCGCCCG CTCCCTTCGC
 10 401 TTTCTTCCCT TCCTTCTCG CCACGTCG CGGCTTCCCC CGTCAAGCTC
 451 TAAATCAGGGG GCTCCCTTAA GGTTCCGAT TTAGTGCCTT ACGGCACCTC
 501 GACCCCAAAA AACTGATTA GGTTGATGGT TCACGTAGTG GGCCATCGCC
 551 CTGATAGACG GTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTATA
 601 GTGGACTCTT GTTCCAAACT GGAACAAACAC TCAACCCATT CTCGGTCTAT
 15 651 TCTTTGATT TATAAGGGAT TTTGCCGATT TCGGCCTATT GGTTAAAAAA
 701 TGAGCTGATT TAACAAAAAT TTAACCGGAA TTTAACAAA ATATTAACGT
 751 TTACAATTTC AGGTGGCACT TTTCGGGAA ATGTGCGCGG AACCCCTATT
 801 TGTTTATTTC TCTAAATACA TTCAAATATG TATCCGCTCA TGAATTAAATT
 851 CTTAGAAAAA CTCATCGAGC ATCAAATGAA ACTGCAATT ATTCAATATCA
 20 901 GGATTATCAA TACCATATT TTGAAAAAGC CGTTCTGTA ATGAAGGAGA
 951 AAACTCACCG AGGCAGTTCG ATAGGATGGC AAGATCCTGG TATCGGTCTG
 1001 CGATTCCGAC TCGTCCAAC TCAATACAC CTATTAATT CCCCTCGTCA
 1051 AAAATAAGGT TATCAAGTGA GAAATCACCA TGAGTGCAGA CTGAATCCGG
 1101 TGAGAATGGC AAAAGTTTAT GCATTTCTT CCAGACTTGT TCAACAGGCC
 25 1151 AGCATTACG CTCGTCATCA AAATCACTCG CATCAACCAA ACCGTTATT
 1201 ATTCGTGATT GCGCCTGAGC GAGACGAAAT ACGCGATCGC TGTTAAAAGG
 1251 ACAATTACAA ACAGGAATCG AATGCAACCG GCGCAGGAAC ACTGCCACCG
 1301 CATCAACAAT ATTTCACCT GAATCAGGAT ATTCTTCTAA TACCTGGAAT
 1351 GCTGTTTCC CGGGGATCGC AGTGGTGAGT AACCATGCAT CATCAGGAGT
 30 1401 ACGGATAAAA TGCTTGATGG TCGGAAGAGG CATAAAATTCC GTCAGCCAGT
 1451 TTAGTCTGAC CATCTCATCT GTAACATCAT TGGCAACGCT ACCTTTGCCA
 1501 TGTTTCAGAA ACAACTCTGG CGCATCGGGC TTCCCATACA ATCGATAGAT
 1551 TGTGCGCACCT GATTGCCGGA CATTATCGCG AGCCCATTTA TACCCATATA
 1601 AATCAGCATC CATGTTGGAA TTTAATCGCG GCCTAGAGCA AGACGTTCC
 35 1651 CGTTGAATAT GGCTCATAAC ACCCCCTGTA TTACTGTTTA TGTAAGCAGA
 1701 CAGTTTATT GTTCATGACC AAAATCCCTT AACGTGAGTT TTCGTTCCAC
 1751 TGAGCGTCAG ACCCCGTAGA AAAGATCAA GGATCTTCTT GAGATCCTTT
 1801 TTTTCTGCGC GTAATCTGCT GCTTGCAAAC AAAAAAAACCA CCGCTACCA
 1851 CGGTGGTTTG TTGCGCGAT CAAGAGCTAC CAACTCTTT TCCGAAGGTA
 40 1901 ACTGGCTCA GCAGAGCGCA GATAACAAAT ACTGCTCTTC TAGTGTAGCC
 1951 GTAGTTAGGC CACCACTTCA AGAACTCTGT AGCACCGCCT ACATACCTCG
 2001 CTCTGCTAAT CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT
 2051 CTTACCGGGT TGGACTCAAG ACGATAGTTA CCGGATAAGG CGCAGCGGTC
 2101 GGGCTGAACG GGGGGTTCGT GCACACAGCC CAGCTGGAG CGAACGACCT
 45 2151 ACACCGAACT GAGATACCTA CAGCGTGAGC TATGGAAAAG CGCCACGCTT
 2201 CCCGAAGGGG GAAAGGCGGA CAGGTATCCG GTAAGCGGCA GGGTCGGAAC
 2251 AGGAGAGCGC ACGAGGGGAGC TTCCAGGGGG AAACGCGCTGG TATCTTTATA
 2301 GTCCTGTCGG GTTTCGCCAC CTCTGACTTG AGCGTCGATT TTGATGTC
 2351 TCGTCAGGGG GCGGGAGCCT ATGGAAAAAC GCCAGCAACG CGGCCTTTTT
 50 2401 ACGGTTCTG GCCTTTGCT GGCCTTTGTC TCACATGTT TTTCTGCGT
 2451 TATCCCCGTA TTCTGTGGAT AACCGTATTA CCGCCTTGT GTGAGCTGAT
 2501 ACCGCTCGCC GCAGCCGAAC GACCGAGCGC AGCGAGTCAG TGAGCGAGGA
 2551 AGCGGAAGAG CGCCTGATGC GGTATTCT CCTTACGCAT CTGTGCGGTA
 2601 TTTCACCCG CATATATGGT GCACTCTCAG TACAATCTGC TCTGATGCCG
 55 2651 CATAGTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC TGGGTCATGG
 2701 CTGCGCCCCG ACACCCGCCA ACACCCGCTG ACGCGCCCTG ACGGGCTTGT
 2751 CTGCTCCCGG CATCCGCTTA CAGACAAAGCT GTGACCGTCT CCGGGAGCTG
 2801 CATGTGTCAG AGGTTTCAC CGTCATCACC GAAACGCGCG AGGCAGCTGC
 2851 GGTAAAGCTC ATCAGCGTGG TCGTGAAGCG ATTACACAGAT GTCTGCCTGT
 60 2901 TCATCCCGGT CCAGCTCGTT GAGTTCTCC AGAAGCGTTA ATGTCTGGCT

	2951	TCTGATAAAAG	CGGGCCATGT	TAAGGGCGGT	TTTTCCGT	TTGGTCACTG
	3001	ATGCCTCCGT	GTAAGGGGGA	TTCTGTTCA	TGGGGTAAT	GATACCGATG
5	3051	AAACGAGAGA	GGATGCTCAC	GATACGGGTT	ACTGATGATG	AACATGCCCG
	3101	GTTACTGGAA	CGTTGTGAGG	GTAAACAACT	GGCGGTATGG	ATGCGGCGGG
	3151	ACCAGAGAAA	AATCACTCAG	GGTCAATGCC	AGCGCTTCGT	TAATACAGAT
	3201	GTAGGTGTTG	CACAGGGTAG	CCAGCAGCAT	CCTGCGATGC	AGATCCGGAA
	3251	CATAATGGTG	CAGGGCGCTG	ACTCCCGGT	TTCCAGACTT	TACGAAACAC
10	3301	GGAAACCGAA	GACCATTAT	GTTGTTGCTC	AGGTCCAGA	CGTTTGCA
	3351	CAGCAGTCGC	TTCACGTTCG	CTCGCGTATC	GGTGAATTAT	TCTGCTAAC
	3401	AGTAAGGCAA	CCCCGCCAGC	CTAGCCGGGT	CCTCAACGAC	AGGAGCACGA
	3451	TCATGCGCAC	CCGTGGGGCC	GCCATGCCGG	CGATAATGGC	CTGCTTCTCG
	3501	CCGAAACGTT	TGGTGGCGGG	ACCACTGACG	AAGGCTTGAG	CGAGGGCGTG
	3551	CAAGATTCCG	AATACCGCAA	GCGACAGGCC	GATCATCGTC	GGCCTCCAGC
15	3601	GAAAGCGGTC	CTCGCCGAAA	ATGACCCAGA	GCGCTGCCGG	CACCTGTCC
	3651	ACGAGTTGCA	TGATAAAAGAA	GACAGTCATA	AGTGCAGCGA	CGATAGTCAT
	3701	GCCCCCGCCC	CACCGGAAGG	AGCTGACTGG	GTTGAAGGCT	CTCAAGGGCA
	3751	TCGGTCGAGA	TCCCGGTGCC	TAATGAGTGA	GCTAACTTAC	ATTAATTGCG
	3801	TTGCGCTCAC	TGCCCCCTT	CCAGTCGGGA	AACCTGTCGT	GCCAGCTGCA
20	3851	TTAATGAATC	GGCCAACGCG	CGGGGGAGAGG	CGGTTGCGT	ATTGGCGGCC
	3901	AGGGTGGTTT	TTCTTTTAC	CAGTGAGACG	GGCACACAGCT	GATTGCCCTT
	3951	CACCGCCTGG	CCCTGAGAGA	GTTGCAGCAA	GGGGTCCACG	CTGGTTGCC
	4001	CCAGCAGGCC	AAAATCCTGT	TTGATGGTGG	TAAACGGCGG	GATATAACAT
	4051	GAGCTGTCTT	CGGTATCGTC	GTATCCCAC	ACCGAGATAT	CCGCACCAAC
25	4101	GCGCAGCCCC	GAECTCGTAA	TGGCGCGCAT	TGCGCCCAGC	GCCATCTGAT
	4151	CGTTGGCAAC	CAGCATCGCA	GTGGGAACGA	TGCCCTCATT	CAGCATTG
	4201	ATGGTTTGGT	GAAAACCGGA	CATGGCACTC	CAGTCGCCTT	CCCGTTCCGC
	4251	TATCGGCTGA	ATTTGATTGC	GAGTGAGATA	TTTATGCCAG	CCAGCCAGAC
	4301	GCAGACGCCG	CGAGACAGAA	CTTAATGGGC	CCGCTAACAG	CGCGATTG
	4351	TGGTGACCCA	ATGCGACCG	ATGCTCCACG	CCCAGTCGCG	TACCGTCTTC
30	4401	ATGGGAGAAA	ATAATACTGT	TGATGGGTGT	TGGTCAGAG	ACATCAAGAA
	4451	ATAACGCCGG	AACATTAGTG	CAGGCAGCTT	CCACAGCAAT	GGCATCCTGG
	4501	TCATCCAGCG	GATAGTTAAT	GATCAGCCCC	CTGACCCGTT	GCGCGAGAAG
	4551	ATTGTGCACC	GCCGCTTAC	AGGCTTCGAC	GCCGCTTCGT	TCTACCATCG
	4601	ACACCACCAC	GCTGGCACCC	AGTTGATCGG	CGCGAGATTT	AATGCCCGCG
35	4651	ACAATTGCG	ACGGCGCGTG	CAGGGCCAGA	CTGGAGGTGG	CAACGCCAAT
	4701	CAGCAACGAC	TGTTTGCCCG	CCAGTTGTTG	TGCCACCGCG	TTGGGAATGT
	4751	AATTCACTCTC	CGCCATCGCC	GCTTCCACTT	TTTCCCGCGT	TTTCGCAGAA
	4801	ACGTGGCTGG	CCTGGTCAC	CACCGGGGAA	ACGGTCTGAT	AAGAGACACC
	4851	GGCATACTCT	GGCACATCGT	ATAACGTTAC	TGGTTTCACA	TTCACCAACCC
40	4901	TGAATTGACT	CTCTTCCGGG	CGCTATCATG	CCATACCGCG	AAAGGTTTTG
	4951	CGCCATTCTGA	TGGTGCCGG	GATCTCGACG	CTCTCCCTTA	TGGGACTCCT
	5001	GCATTAGGAA	GCAGCCCCAGT	AGTAGGTTGA	GGCCGTTGAG	CACCGCCGCC
	5051	GCAAGGAATG	GTGCATGCAA	GGAGATGGCG	CCCAACAGTC	CCCCGGCCAC
45	5101	GGGGCCTGCC	ACCATACCCA	CGCCGAAACA	AGCGCTCATG	AGCCCGAAGT
	5151	GGCGAGCCCG	ATCTTCCCCA	TCGGTGATGT	CGGCGATATA	GGGCCAGCA
	5201	ACCGCACCTG	TGGCGCCGGT	GATGCCGGCC	ACGATGCGTC	CGGCGTAGAG
	5251	GATCGAGATC	TCGATCCCGC	GAAATTAAATA	CGACTCACTA	TAGGGGAATT
	5301	GTGAGCGGAT	AAACAATTCCC	CTCTAGAAAT	AATTTGATT	TAACTTTAAG
	5351	AAGGAGATAT	ACCATGAAA			

SEQUENCE LISTING 4

1	AGCGCCCAAT	ACGCAAACCG	CCTCTCCCCG	CGCGTGGGCC	GATTCAATTAA
51	TGCAGCTGGC	ACGACAGGTT	TCCCGACTGG	AAAGCGGGCA	GTGAGCGCAA
101	CGCAATTAAT	GTGAGTTAGC	TCACTCATTA	GGCACCCAG	GCTTTACACT
151	TTATGCTCC	GGCTCGTATG	TTGTGTGGAA	TTGTGAGCGG	ATAACAATT
201	CACACAGGAA	ACAGCTATGA	CCATGATTAC	GCCAAGCTTG	CATGCCTGCA
251	GGTCGACTCT	AGAGGATCCC	CGGGTACCGG	TAGAAAAAAT	GAGTAAAGGA
301	GAAGAACCTT	TCACTGGAGT	TGTCCAATT	CTTGTGAAAT	TAGATGGTGA
351	TGTTAATGGG	CACAAATT	CTGTCAGTGG	AGAGGGTGA	GGTGATGCAA
401	CATACGGAAA	ACTTACCCCTT	AAATTATTT	GCACACTGG	AAAACCTACCT
451	GTTCCATGGC	CAACACTTGT	CACTACTTC	TCTTATGGT	TTCAATGCTT
501	TTCCCGTTAT	CCGGATCATA	TGAAACGGCA	TGACTTTTC	AAGAGTGCCA
551	TGCCCGAAGG	TTATGTACAG	GAACGCACTA	TATCTTCAA	AGATGACGGG
601	AACTACAAGA	CGCGTGCTGA	AGTCAAGTTT	GAAGGTGATA	CCCTGTTAA
651	TCGTATCGAG	TTAAAAGGTA	TTGATTTAA	AGAAGATGGA	ACATTCTCG
701	GACACAACT	CGAGTACAAC	TATAACTCAC	ACAATGTATA	CATCACGGCA
751	GACAAACAAA	AGAATGGAAT	CAAAGCTAAC	TTCAAAATT	GCCACAAACAT
801	TGAAGATGGA	TCCGGTCAAC	TAGCAGACCA	TTATCAACAA	AATACTCCAA
851	TTGGCGATGG	CCCTGTCCTT	TTACCAGACA	ACCATTACCT	GTGCGACACAA
901	TCTGCCCTT	CGAAAGATCC	CAACGAAAAG	CGTGACCACA	TGGTCCTTCT
951	TGAGTTTGTA	ACTGCTGCTG	GGATTACACA	TGGCATGGAT	GAGCTCTACA
1001	AATAATGAAT	TCCAAGTACTGAG	CGCCGGTGC	TACATTACC	AACTTGTCTG
1051	GTGTCAAAAA	TAATAGGCCT	ACTAGTCGGC	CGTACGGGCC	CTTCGTCTC
1101	GCGCGTTCG	GTGATGACGG	TGAAAACCTC	TGACACATGC	AGCTCCCGGA
1151	GACGGTCACA	GCTTGTCTGT	AAGCGGATGC	CGGGGAGCAGA	CAAGCCCGTC
1201	AGGGCGCGTC	AGCGGGTGT	GGCGGGTGT	GGGGCTGGCT	TAACTATGCG
1251	GCATCAGAGC	AGATTGTACT	GAGAGTGCAC	CATATCGGGT	GTGAAATACC
1301	GCACAGATGC	GTAAGGAGAA	AATACCGCAT	CAGGCGGCCT	TAAGGGCCTC
1351	GTGATACGCC	TATTTTATA	GGTTAATGTC	ATGATAATAA	TGGTTTCTTA
1401	GACGTCAGGT	GGCACTTTC	GGGGAAATGT	GCAGCGGAACC	CCTATTGTT
1451	TATTTTCTA	AATACATTCA	AATATGTATC	CGCTCATGAG	ACAATAACCC
1501	TGATAAATGC	TCACAATAATA	TTGAAAAAGG	AAGAGTATGA	GTATTCAACA
1551	TTTCCGTGTC	GCCCTTATT	CCTTTTTGTC	GGCATTTGC	CTTCCTGTT
1601	TTGCTCACCC	AGAAACGCTG	GTGAAAGTAA	AAGATGCTGA	AGATCAGTTG
1651	GGTGCACGAG	TGGGTTACAT	CGAACGGAT	CTCAACAGCG	CTAACATCCT
1701	TGAGAGTTT	CGCCCCGAAG	AACGTTTCC	AATGATGAGC	ACTTTAAAG
1751	TTCTGCTATG	TGGCGCGTA	TTATCCCGTA	TTGACGCCGG	GCAAGAGCAA
1801	CTCGGTGCC	GCATACACTA	TTCTCAGAAT	GACTTGGTTG	AGTACTCACC
1851	AGTCACAGAA	AAGCATCTTA	CGGATGGCAT	GACAGTAAGA	GAATTATGCA
1901	GTGCTGCAT	AACCATGAGT	GATAACACTG	CGGCCAACCT	ACTTCTGACA
1951	ACGATCGGAG	GACCGAAGGA	GCTAACCGCT	TTTTGCACA	ACATGGGGGA
2001	TCATGTA	CGCCCTGATC	GTTGGAAACC	GGAGCTGAAT	GAAGCCATAC
2051	CAAACGACGA	GGTGTACACC	ACGATGCC	TAGCAATGGC	AACAACGTTG
2101	CGCAAACAT	TAACTGGCGA	ACTACTTACT	CTAGCTTCCC	GGCAACAATT
2151	AATAGACTGG	ATGGAGGCGG	ATAAAGTTC	AGGACCACTT	CTGCGCTCGG
2201	CCCTTCCGGC	TGGCTGGTT	ATTGCTGATA	AATCTGGAGC	CGGTGAGCGT
2251	GGGTCTCGCG	GTATCATTGC	AGCACTGGGG	CCAGATGGTA	AGCCCTCCCG
2301	TATCGTAGTT	ATCTACACGA	CGGGGAGTCA	GGCAACTATG	GATGAACGAA
2351	ATAGACAGAT	CGCTGAGATA	GGTGCCTCAC	TGATTAAGCA	TTGGTAACTG
2401	TCAGACCAAG	TTTACTCTATA	TATACTTTAG	ATTGATTTAA	AACTTCATT
2451	TTAATTTAAA	AGGATCTAGG	TGAAGATCCT	TTTTGATAAT	CTCATGACCA
2501	AAATCCCTTA	ACGTGAGTTT	TCGTTCCACT	GAGCCTCAGA	CCCCGTAGAA
2551	AAGATCAAAG	GATCTCTTG	AGATCCTTT	TTTCTGCGCG	TAATCTGCTG
2601	CTTGCAAAACA	AAAAAAACCAC	CGCTACCGC	GGTGGTTGT	TTGCCGGATC
2651	AAGAGCTACC	AACTCTTTT	CCGAAGGTA	CTGGCTTCAG	CAGAGCGCAG
2701	ATACCAAATA	CTGTCCTTCT	AGTGTAGCG	TAGTTAGGCC	ACCAACTTCAA
2751	GAACTCTGTA	GCACCGCCTA	CATACCTCGC	TCTGCTAATC	CTGTTACCA
2801	TGGCTGCTGC	CAGTGGCGAT	AAGTCGTGTC	TTACCGGGTT	GGACTCAAGA
2851	CGATAGTTAC	CGGATAAGGC	GCAGCGGTG	GGCTGAACGG	GGGGTTCGTG
2901	CACACAGCCC	AGCTTGGAGC	GAACGACCTA	CACCGAACTG	AGATACCTAC

2951 AGCGTGAGCT ATGAGAAAGC GCCACGCTTC CCGAAGGGAG AAAGGCAG
3001 AGGTATCCGG TAAGCGCAG GGTCGGAACA GGAGAGCGCA CGAGGGAGCT
3051 TCCAGGGGGA AACGCCCTGGT ATCTTTATAG TCCTGTCGGG TTTGCCACC
3101 TCTGACTTGA GCGTCGATT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA
5 3151 TGAAAACG CCAGCAACGC GGCCTTTTA CGGTTCCCTGG CCTTTGCTG
3201 GCCTTTGCT CACATGTTCT TTCCTGCGTT ATCCCCCTGAT TCTGTGGATA
3251 ACCGTATTAC CGCCTTGAG TGAGCTGATA CCGCTCGCCG CAGCCGAACG
3301 ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA GCGGAAG

SEQUENCE LISTING 5

1	ATGAAACATC	ACCATCACCA	TCACCCCATG	AGCGATTACG	ACATCCCCAC	
51	TACTGAGAAT	CTTATTTC	AGGGCGCCAT	GGGAGGCACG	GTACCGGTAG	
101	AAAAAATGAG	TAAAGGAGAA	GAACTTTCA	CTGGAGTTGT	CCCAATTCTT	
5	151	GTTGAATTAG	ATGGTGATGT	TAATGGGCAC	AAATTTCCTG	TCAGTGGAGA
201	GGGTGAAGGT	GATGCAACAT	ACGGAAAACT	TACCCCTAAA	TTTATTGCA	
251	CTACTGGAAA	ACTACCTGTT	CCATGGCCAA	CACTGTCAC	TACTTTCTCT	
301	TATGGTGTTC	AATGCTTTTC	CCGTTATCCG	GATCATATGA	AACGGCATGA	
351	CTTTTCAAG	AGTGCCATGC	CCGAAGGTTA	TGTACAGGAA	CGCACTATAT	
10	401	CTTTCAAAAGA	TGACGGGAAC	TACAAGACGC	GTGCTGAAGT	CAAGTTGAA
451	GGTGATAACCC	TTGTTAACATCG	TATCGAGTTA	AAAGGTATTG	ATTTTAAAGA	
501	AGATGAAAC	ATTCTCGGAC	ACAAACTCGA	GTACAACATAT	AACTCACACA	
551	ATGTATACAT	CACGGCAGAC	AAACAAAAGA	ATGGAATCAA	AGCTAACTTC	
601	AAAATTGCGC	ACAACATTGA	AGATGGATCC	GTTCACATAG	CAGACCATTAA	
15	651	TCAACAAAAT	ACTCCAATTG	GCGATGGCCC	TGTCCTTTA	CCAGACAAACC
701	ATTACCTGTC	GACACAATCT	GCCCCTTCGA	AAGATCCCAA	CGAAAAGCGT	
751	GACCACATGG	TCCCTCTTGA	GTTCGTAACT	GTCGCTGGGA	TTACACATGG	
801	CATGGATGAG	CTCCGTCGAC	AAGCTTGCAG	CCGCACTCGA	GCACCACAC	
851	CACCACCACT	GAGATCCGGC	TGCTAACAAA	GCCCCGAAAGG	AAGCTGAGTT	
20	901	GGCTGCTGCC	ACCGCTGAGC	AATAACTAGC	ATAACCCCTT	GGGGCCTCTA
951	AACGGGTCTT	GAGGGGTTT	TTGCTGAAAG	GAGGAACATAT	ATCCGGATTTG	
1001	GCGAATGGGA	CGCGCCCTGT	AGCGGCCAT	TAAGCGCGC	GGGTGTGGTG	
1051	GTTACCGC	GCGTGACCGC	TACACTTGCC	AGCGCCCTAG	CGCCCGCTCC	
1101	TTTCGCTTTC	TTCCCTTCCT	TTCTCGCCAC	GTCGCGCCGGC	TTTCCCCGTC	
25	1151	AAGCTCTAA	TCCGGGGCCTC	CCTTTAGGGT	TCCGATTTAG	TGCTTTACGG
1201	CACCTCGACC	CCAAAAAAACT	TGATTAGGGT	GATGGTTCAC	GTAGTGGGCC	
1251	ATCGCCCTGA	TAGACGGTTT	TTCGCCCTTT	GACCTGGAG	TCCACGTTCT	
1301	TTAATAGTGG	ACTCTTGTTC	CAAACCTGAA	CAACACTCAA	CCCTATCTCG	
1351	GTCTATTCTT	TTGATTTATA	AGGGATTTCG	CCGATTTCCG	CCTATTGGTT	
30	1401	AAAAAATGAG	CTGATTTAAC	AAAAATTAA	CGCGAATTTC	AACAAAATAT
1451	TAACGTTAC	AATTCAGGT	GGCACTTTT	GGGGAAATGT	GCGCGGAACC	
1501	CCTATTGTT	TATTTTCTA	AATACATCA	AATATGTATC	CGCTCATGAA	
1551	TTAATTCTT	AAAAAACTCA	TCGAGCATCA	AATGAAACTG	CAATTTATTC	
1601	ATATCAGGAT	TATCAATACC	ATATTTTGA	AAAAGCCGTT	TCTGTAATGA	
35	1651	AGGAGAAAAC	TCACCGAGGC	AGTTCCATAG	GATGCCAAGA	TCCTGGTATC
1701	GGTCTCGCAT	TCCGACTCGT	CCAACATCAA	TACAACCTAT	TAATTCCCC	
1751	TCGTCAAAAA	TAAGGTTATC	AAGTGAGAAA	TCACCATGAG	TGACGACTGA	
1801	ATCCGGTAG	AATGGCAAAA	GTTCATGCA	TTCTTCCAG	ACTTGTCAA	
1851	CAGGCCAGCC	ATTACGCTCG	TCATCAAAT	CACTCGCATE	AACCAAACCG	
40	1901	TTATTCAATT	GTGATTGCGC	CTGAGCGAGA	CGAAATACGC	GATCGCTGTT
1951	AAAAGGACAA	TTACAAACAG	GAATCGAATG	CAACCGGCC	AGGAACACTG	
2001	CCAGCGCATC	AACAATATT	TCACCTGAAT	CAGGATATT	TTCTAATACC	
2051	TGGAATGCTG	TTTCCCGGG	GATCGCAGT	GTGAGTAACC	ATGCATCATC	
2101	AGGAGTACGG	ATAAAATGCT	TGATGGTCGG	AAGAGGCATA	AATTCCGTCA	
45	2151	GCCAGTTAG	TCTGACCATC	TCATCTGTAA	CATCATTGGC	AACGCTACT
2201	TTGCCATGTT	TCAGAAACAA	CTCTGGCGC	TCGGGCTTCC	CATACAATCG	
2251	ATAGATGTC	GCACCTGATT	GCCCCGACATT	ATCCGAGGCC	CATTATACC	
2301	CATATAAAC	AGCATCCATG	TTGGAATT	ATCCGGGCCT	AGAGCAAGAC	
2351	TTTCCCGTT	GAATATGGCT	CATAACACCC	CTTGTATTAC	TGTTTATGTA	
50	2401	AGCAGACAGT	TTTATTGTT	ATGACCAAAA	TCCCTTAACG	TGAGTTTCG
2451	TTCCACTGAG	CGTCAGACCC	CGTAGAAAAG	ATCAAAGGAT	CTTCTTGAGA	
2501	TCCTTTTTT	CTGCGCGTAA	TCTGCTGCTT	GAAACAAAAA	AAACCAACGC	
2551	TACCAGCGGT	GGTTTGTTCG	CCGGATCAAG	AGCTACCAAC	TCTTTTCCG	
2601	AAGGTAAC	GCTTCAGCAG	AGCGCAGATA	CCAAATACTG	TCCTTCTAGT	
55	2651	GTAGCCGTAG	TTAGGCCACC	ACTTCAAGAA	CTCTGTAGCA	CCGCCTACAT
2701	ACCTCGCTCT	GCTAATCCTG	TTACCACTGG	CTGCTGCCAG	TGGCGATAAG	
2751	TCGTGTCTT	CCGGGTTGGA	CTCAAGACGA	TAGTTACCGG	ATAAGGCGCA	
2801	GCGGTGGGGC	TGAACGGGGG	GTTCGTGAC	ACAGCCCAGC	TTGGAGCGAA	
2851	CGACCTACAC	CGAACTGAGA	TACCTACAGC	GTGAGCTATG	AGAAAGCGCC	
60	2901	ACGCTTCCC	AAGGGAGAAA	GGCGGACAGG	TATCCGGTAA	CGGGCAGGGT
2951	CGGAACAGGA	GAGCGCACGA	GGGAGCTCC	AGGGGAAAC	GCCTGGTATC	

3001 TTTATAGTCC TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTG
 3051 TGATGCTCGT CAGGGGGCG GAGCCTATGG AAAAACGCCA GCAACGCGGC
 3101 CTTTTTACGG TTCTCTGGCCT TTTGCTGGCC TTTTGCTCAC ATGTTCTTTC
 3151 CTGCGTTATC CCCTGATTCT GTGGATAACC GTATTACCGC CTTTGAGTGA
 5 3201 GCTGATAACCG CTCGCCGCAG CGGAACGCG GAGGCCAGCG AGTCAGTGAG
 3251 CGAGGAAGCG GAAGAGCGCC TGATGCGTA TTTTCTCCCT ACCGCATCTGT
 3301 CGGGTATTTCA ACACCGCATA TATGGTGAC TCTCAGTACA ATCTGCTCTG
 3351 ATGCCGCATA GTTAAGCCAG TATACACTCC GCTATCGCTA CGTGAUTGGG
 3401 TCATGGCTGC GCCCCGACAC CGCCAACAC CCGCTGACGC GCCCTGACGG
 10 3451 GCTTGTCTGC TCCCAGCAGA CGCTTACAGA CAAGCTGTGA CGGTCTCCGG
 3501 GAGCTGCATG TGTCAAGAGGT TTTCACCGTC ATCACCGAAA CGCGCGAGGC
 3551 AGCTGCGGTA AAGCTCATCA GCGTGGTCGT GAAGCGATT ACAGATGCT
 3601 GCCTGTTCAT CCGCGTCCAG CTCGTTGAGT TTCTCCAGAA CGTAAATGTT
 3651 CTGGCTTCTG ATAAAGCGGG CCATGTTAAG GGCGGTTTT TCCTGTTGG
 15 3701 TCACTGATCG CTCCTGTAA GGGGGATTTG TGTTCATGGG GGTAAATGATA
 3751 CCGATGAAAC GAGAGAGGAT GCTCACGATA CGGGTTACTG ATGATGAACA
 3801 TGCCCGGTTA CTGGAACGTT GTGAGGGTAA ACAACTGGCG GTATGGATGC
 3851 GGCAGGGACCA GAGAAAAATC ACTCAGGGTC AATGCCAGCG CTTCGTTAAT
 3901 ACAGATGTAG GTGTTCCACA GGGTAGCCAG CAGCATCTG CGATGCAAGAT
 20 3951 CGGAAACATA ATGGTGCAGG GCGCTGACTT CCGCGTTTC AGACTTTACG
 4001 AAACACGGAA ACCGAAGACC ATTCACTGTT TGCTCAGGT CGCAGACGTT
 4051 TTGCAGCAGC AGTCGCTTC CGTTCGCTCG CGTATCGGTG ATTCAATTCTG
 4101 CTAACCAAGTA AGGCAACCCCC CGCAGCCTAG CGGGGTCCCT AACGACAGGA
 4151 GCACGATCAT GCGCACCCGT GGGGCCGCCA TGCCGGCGAT ATGGCCTGC
 25 4201 TTCTCGCCGA AACGTTTGGT GGCAGGGACCA GTGACGAAGG CTTGAGCGAG
 4251 GGCCTGCAAG ATTCCGAAATA CCGCAAGCGA CAGGGCGATC ATCGTCGCGC
 4301 TCCAGCGAAA GCGGCCTCG CCGAAAATGA CCCAGAGCGC TGCCGGCAC
 4351 TGTCTTACGA GTTGCATGAT AAAGAAAGACA GTCTAAAGTG CGGCCGACGAT
 4401 AGTCATGCCCG CCGGCCAAC CCAAGGGAGCT GACTGGTTG AAGGCTCTCA
 30 4451 AGGGCATCGG TCGAGATCCC GGTGCTTAAT GAGTGAGCTA ACTTACATTA
 4501 ATTGCGTTGC GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA
 4551 GCTGCATTAA TGAATCGGCC AACCGCGGG GAGAGGCGGT TTGCGTATTG
 4601 GGCGCCAGGG TGGTTTTCT TTTCACCAAGT GAGACGGGCA ACAGCTGATT
 4651 GCCCTTCACC GCCTGGCCCT GAGAGGTTG CAGCAAGCGG TCCACGCTGG
 35 4701 TTTGCCCGAG CAGGCAGAAA TCCCTGTTGA TGGTGGTTAA CGGCAGGGATA
 4751 TAACATGAGC TGTCTTCGGT ATCGTCGTAT CCCACTACCG AGATATCCGC
 4801 ACCAACCGCG ACCCGCGACT CGGTAATGGC GCGCATTGCG CCCAGCGCCA
 4851 TCTGATCGTT GGCAACCAGC ATCGCAGTGG GAACGATGCC CTCATTCA
 4901 ATTGCGATGG TTTGTTGAAA ACCGGACATG GCACTCCAGT CGCCCTTCCCG
 40 4951 TTCCGCTATC GGCTGAATT GATTGCGAGT GAGATATTAA TGCCAGGCCAG
 5001 CCAGACCGAG ACAGCGCCGAG ACAGAACTTA ATGGGCCCGC TAACAGCGCG
 5051 ATTTGCTGGT GACCAATGC GACCAGATGC TCCACGCCA GTCGCGTACC
 5101 GTCTTCATGG GAGAAAATAA TACTGTTGAT GGGTGTCTGG TCAGAGACAT
 5151 CAAGAAATAA CGCCGGAAACA TTAGTGCAGG CAGCTTCCAC AGCAATGGCA
 45 5201 TCCTGGTCAT CCAGCGGATA GTTAATGATC AGCCCACTGA CGCGTTGCGC
 5251 GAGAAAGATTG TGACCCGGCG CTTTACAGGC TTGACGCCG CTTCGTTCTA
 5301 CCATCGACAC CACCCAGCTG GCACCCAGTG GATCGCGCGC AGATTTAAC
 5351 GCGCGCAA TTTGCGACGG CGCGTGCAGG GCCAGACTGG AGGTGGCAAC
 5401 GCGAACATCAGC AACGACTGTT TGCCCCGAG TTGTTGTCGCC ACAGCGGTTGG
 50 5451 GAATGTAATT CAGCTCCGCC ATCGCCGTT CCACCTTTTC CGCGTTTTTC
 5501 GCAGAAACGT GGCTGGCCTG GTTCACCAAGC CGGGAAACGG TCTGATAAGA
 5551 GACACCGGCA TACTCTGCGA CATCGTATAA CGTTACTGGT TTCACATTCA
 5601 CCACCCCTGAA TTGACTCTCT TCCGGGCCCT ATCATGCCAT ACCCGCGAAAG
 5651 GTTTGCGCC ATTGATGGT GTCCGGGATC TCGACGCTCT CCCTTATGCG
 55 5701 ACTCCTGCAT TAGGAAGCAG CCCAGTAGTA GGTTGAGGCC GTTGAGCACC
 5751 GCCGCCGCAA GGAATGGTGC ATGCAAGGAG ATGGCGCCCA ACAGTCCCCC
 5801 GGCCACGGGG CCTGCCACCA TACCCACGCC GAAACAAAGCG CTCATGAGCC
 5851 CGAAGTGGCG AGCCCGATCT TCCCCATCGG TGATGTCGGC GATATAGGCC
 5901 CCAGCAACCG CACCTGTGGC GCGGGTGATC CGGGCCACGA TGCGTCCGGC
 60 5951 GTAGAGGATC GAGATCTCGA TCCCGCAGAA TTAATACGAC TCACTATAGG
 6001 GGAATTGTAAGC GCGATAACA ATTCCCTCT AGAAATAATT TTGATTAAAC
 6051 TTTAAGAAGG AGATATAAC

CLAIMS

- 1) Circular recombinant plasmid DNA construct encoding a) a protein tag, b) a visual marker protein, and containing c) a multiple cloning site suitable for insertion of an additional gene, characterised in that the gene sequence encoding the protein tag and the visual marker protein are specifically designed and engineered at the DNA level for respectively a) immobilisation purposes and b) visualisation and quantification purposes at the protein level.
5
- 2) Construct according to claim 1, characterised in that the protein tag is chosen from the group containing lysine (lys), histidine (his), tyrosine (tyr), phenylalanine (phe), arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate, asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val), tryptophan (trp).
10
- 3) Construct according to claim 1 or 2, characterised in that the protein tag is a histidine-tag such as a polyhistidine variant, in particular (6X) histidine.
15
- 4) Construct according to any one of the preceding claims, characterised in that the visual marker protein is chosen from the group containing fluorescent or phosphorescent proteins.
20
- 5) Construct according to claim 4, characterised in that the fluorescent protein is chosen from the group containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as their variants and/or mutants.
25
- 6) Construct according to any one of the preceding claims, characterised in that the multiple cloning site contains restriction enzyme recognition sites.
30
- 7) Construct according to claim 6, characterised in that the restriction enzyme recognition site is chosen from the group containing SacI, Sal I, Hind III, Eag I, Not I.
25
- 8) Construct according to any one of the preceding claims, characterised in that it further contains a frame adapter of variable length between the visual marker and protein tag genes.
30
- 9) Protein expressed by circular recombinant plasmid DNA construct according to any one of claims 1 to 8, characterised in that in the MCS adjacent to the visual marker, it further contains an additional target protein and in that the tag is suitable to interact directly with appropriate surface pendant groups of a support material.
30
- 10) Protein according to claim 9 characterised in that it is a fusion protein.

- 11) Use of the protein constructs of claim 9 or 10, in immobilisation and visualisation of proteins on compatible support material.
- 12) Method for preparing and immobilising a protein on a support material, characterised in that it contains the steps of:
 - 5 a) Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a multiple cloning site suitable for insertion of a target protein to be immobilised,
 - 10 b) Inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
 - c) Initiating protein expression.
 - d) Optionally pre-treating the support material;
 - e) Incubating the protein and support material together, wherein the protein is immobilised to the support via specific tag-surface interactions;
 - 15 f) Washing away the non-specific biomolecules;
 - g) Optionally quantifying the fluorescence of the visual marker protein;
 - h) Optionally desorbing the target protein.
- 13) Method according to claim 12, characterised in that the support material is chosen from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.
- 20
- 14) Method according to any one of claims 12 and 13, characterised in that the support material is chosen from the group containing polymers, silicon dioxides, aluminum oxides, titanium oxides, magnesium oxides, borates, metals and other metal oxides.
- 25
- 15) Method according to any one of claims 13 and 14, characterised in that the polymers are chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters polysulfones, polyethersulfones, polyethersulfides, polyimines, polyethyleneglycols, polypropyleneglycols, polyimides, polycarbonates, polyurethanes,
- 30

5 16) Method according to claim 15, characterised in that the polymer surface is chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals.

10 17) Method according to any one of claims 13 to 16, characterised in that the support material is carboxylated polystyrene.

15 18) Immobilised protein construct obtained by the method according to any one of claims 13 to 17, characterised in that it is covalently or non-covalently bonded to the support material.

20 19) Immobilised protein construct according to claim 18, characterised in that it is non-covalent and yet freely accessible and leach-free like proteins immobilised in the covalent sense.

20 20) Use of the immobilised protein constructs according to any one of claims 18 and 19 in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.

[Received by the International Bureau on 04 DEC 2003 (04.12.03);
original claims 1 to 3, unchanged; original claims 4 to 16, amended;
claims 17 to 20, cancelled]

5 1) Circular recombinant plasmid DNA construct encoding a) a protein tag, b) a visual marker protein, and containing c) a multiple cloning site suitable for insertion of an additional gene, characterised in that the gene sequence encoding the protein tag and the visual marker protein are specifically designed and engineered at the DNA level for respectively a) immobilisation purposes and b) visualisation and quantification purposes at the protein level.

10 2) Construct according to claim 1, characterised in that the protein tag is chosen from the group containing lysine (lys), histidine (his), tyrosine (tyr), phenylalanine (phe), arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate, asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val), tryptophan (trp).

15 3) Construct according to claim 1 or 2, characterised in that the protein tag is a histidine-tag such as a polyhistidine variant, in particular (6X) histidine.

20 4) Construct according to any one of the preceding claims, characterised in that the visual marker protein is chosen from the group containing fluorescent or phosphorescent proteins, wherein the fluorescent protein is chosen from the group containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as their variants and/or mutants.

25 5) Construct according to any one of the preceding claims, characterised in that the multiple cloning site contains restriction enzyme recognition sites chosen from the group containing SacI, Sal I, Hind III, Eag I, Not I.

30 6) Construct according to any one of the preceding claims, characterised in that it further contains a frame adapter of variable length between the visual marker and protein tag genes.

 7) Construct according to any one of the preceding claims, characterised in that it expresses a fusion protein, wherein the tag is suitable to interact directly with appropriate surface pendant groups of a support material.

 8) Construct according to claim 9, characterised in that the direct interaction with the support material is covalent or non-covalent.

 9) Construct according to claim 10, characterised in that the direct interaction is non-covalent and yet freely accessible and leach-free like covalent one.

10) Method for preparing and immobilising a protein on a support material, characterised in that it contains the steps of:

- Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a multiple cloning site suitable for insertion of a target protein to be immobilised,
- Inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
- Initiating protein expression.
- Optionally pre-treating the support material;
- Incubating the protein and support material together, wherein the protein is immobilised to the support via specific tag-surface interactions;
- Washing away the non-specific biomolecules;
- Optionally quantifying the fluorescence of the visual marker protein;
- Optionally desorbing the target protein.

11) Method according to claim 10, characterised in that the support material is chosen from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.

12) Method according to any one of claims 10 and 11, characterised in that the support material is chosen from the group containing polymers, silicon dioxides, aluminum oxides, titanium oxides, magnesium oxides, borates, metals and other metal oxides.

13) Method according to any one of claims 11 and 12, characterised in that the polymers are chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters polysulfones, polyethersulfones, polyethersulfides, polyimines, polyethyleneglycols, polypropyleneglycols, polyimides, polycarbonates, polyurethanes,

5 14) Method according to claim 13, characterised in that the polymer surface is chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals.

10 15) Method according to any one of claims 13 to 16, characterised in that the support material is carboxylated polystyrene.

15 16) Method according to claim 10, characterised in that quantifying in step g) of the fluorescence of the visual marker protein is used in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.




Fig. 1

10/550226

2/7




Fig. 2




Fig. 3

10/550226

4/7




Fig. 4




Fig. 5

6/7




Fig. 6




Fig. 7

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.